Morie A Gertz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4240846/publications.pdf

Version: 2024-02-01

1,032	58,453	872 117	1934 207
papers	citations	h-index	g-index

1047	1047	1047	22233
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Outcomes after biochemical or clinical progression in patients with multiple myeloma. Blood Advances, 2023, 7, 909-917.	5.2	7
2	Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)â€“Associated Lesions: A Case Series. American Journal of Kidney Diseases, 2022, 79, 202-216.	1.9	9
3	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia, 2022, 36, 801-808.	7.2	43
4	Foot drop in patients treated with bortezomib â€“ a case series and review of the literature. Leukemia and Lymphoma, 2022, 63, 722-728.	1.3	1
5	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia, 2022, 36, 873-876.	7.2	12
6	Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 1-7.	3.0	42
7	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia, 2022, 36, 1058-1065.	7.2	3
8	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. American Journal of Hematology, 2022, 97, 209-215.	4.1	5
9	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. American Journal of Hematology, 2022, , .	4.1	5
10	Kidney Transplant Outcomes of Patients With Multiple Myeloma. Kidney International Reports, 2022, 7, 752-762.	0.8	7
11	A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 21.	6.2	30
12	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia, 2022, 36, 1426-1428.	7.2	7
13	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. American Journal of Hematology, 2022, , .	4.1	2
14	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematology,the, 2022, 9, e143-e161.	4.6	44
15	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio â‰¥100. Leukemia, 2022, 36, 1429-1431.	7.2	8
16	Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma. Blood Advances, 2022, , .	5.2	11
17	Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Advances, 2022, 6, 2763-2772.	5.2	13
18	Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. Bone Marrow Transplantation, 2022, 57, 803-809.	2.4	6

#	Article	IF	Citations
19	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplantation, 2022, , .	2.4	0
20	Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia. Hematology/Oncology Clinics of North America, 2022, 36, 341-352.	2.2	7
21	Long term survival in multiple myeloma: a single institution experience in underprivileged circumstances. Leukemia and Lymphoma, 2022, 63, 1236-1241.	1.3	2
22	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. Blood Cancer Journal, 2022, 12, 59.	6.2	3
23	Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. American Journal of Hematology, 2022, 97, 818-829.	4.1	39
24	Intraocular plasmacytoma: A case of iris involvement and a review of the literature. American Journal of Ophthalmology Case Reports, 2022, 26, 101533.	0.7	1
25	Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. Transplantation and Cellular Therapy, 2022, 28, 473-482.	1.2	20
26	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 2022, 63, 2422-2427.	1.3	2
27	Smoldering multiple myeloma: Reviewing the rationale for intervention. Leukemia and Lymphoma, 2022, 63, 2033-2040.	1.3	2
28	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. JCO Oncology Practice, 2022, , OP2100789.	2.9	0
29	Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for WaldenstrÃ¶m macroglobulinemia (WM): An international collaborative study.. Journal of Clinical Oncology, 2022, 40, 7566-7566.	1.6	9
30	Waldenstrom Macroglobulinemia: Tailoring Therapy for the Individual. Journal of Clinical Oncology, 2022, 40, 2600-2608.	1.6	3
31	Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. Blood Advances, 2022, 6, 5429-5435.	5.2	3
32	Birtamimab in patients with Mayo stage IV AL amyloidosis: Rationale for confirmatory affirm-AL phase 3 study.. Journal of Clinical Oncology, 2022, 40, TPS8076-TPS8076.	1.6	6
33	Impact of high-dose melphalan followed by autologous stem cell transplant in producing MRD negative complete response in newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2022, 40, e20001-e20001.	1.6	0
34	Sarcopenia identified by computed tomography (CT) imaging using a machine learningâ€“based convolutional neural network (CNN) algorithm impacts survival in patients with newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2022, 40, 110-110.	1.6	1
35	Cardiac Amyloidosis. Heart Failure Clinics, 2022, 18, 479-488.	2.1	4
36	Insurance-based disparities in Waldenstrom Macroglobulinemia: An NCDB analysis.. Journal of Clinical Oncology, 2022, 40, e19562-e19562.	1.6	0

#	Article	IF	Citations
37	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 274-277.	2.4	1
38	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. Kidney International, 2021, 99, 707-715.	5.2	13
39	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 475-483.	4.7	45
40	Outcomes of multiple myeloma patients with <scp>del 17p</scp> undergoing autologous stem cell transplantation. American Journal of Hematology, 2021, 96, E35-E38.	4.1	2
41	Characterization and prognostic implication of delayed complete response in AL amyloidosis. European Journal of Haematology, 2021, 106, 354-361.	2.2	4
42	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal of Haematology, 2021, 106, 433-436.	2.2	3
43	Autologous stem cell transplantation for multiple myeloma patients aged â‰¥ 75 treated with novel agents. Bone Marrow Transplantation, 2021, 56, 1144-1150.	2.4	15
44	Implications of detecting serum monoclonal protein by MASSâ€fix following stem cell transplantation in multiple myeloma. British Journal of Haematology, 2021, 193, 380-385.	2.5	21
45	Partial response or better at sixÂmonths is prognostic of superior progressionâ€free survival in WaldenstrÃ¶m macroglobulinaemia patients treated with ibrutinib. British Journal of Haematology, 2021, 192, 542-550.	2.5	8
46	Nonâ€cardiac biopsy sites with high frequency of transthyretin amyloidosis. ESC Heart Failure, 2021, 8, 750-755.	3.1	7
47	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (<scp>VRd</scp>) as firstâ€line therapy in multiple myeloma. American Journal of Hematology, 2021, 96, 330-337.	4.1	13
48	Use of autologous stem cells cryopreserved for over 15 years in stem cell transplantation for multiple myeloma. Bone Marrow Transplantation, 2021, 56, 978-979.	2.4	0
49	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplantation, 2021, 56, 928-935.	2.4	5
50	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 309.e1-309.e5.	1.2	1
51	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 308-315.	1.3	3
52	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. Leukemia and Lymphoma, 2021, 62, 316-322.	1.3	2
53	Current and Emerging Treatments for WaldenstrÃ¶m Macroglobulinemia. Acta Haematologica, 2021, 144, 146-157.	1.4	7
54	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 460-474.	4.7	67

#	Article	IF	Citations
55	Systemic amyloidosis from A (AA) to T (ATTR): a review. Journal of Internal Medicine, 2021, 289, 268-292.	6.0	133
56	Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. Journal of Neurology, 2021, 268, 2109-2122.	3.6	141
57	Amyloid arthropathy in smoldering myeloma: Do not take it lightly. Leukemia Research Reports, 2021, 15, 100242.	0.4	2
58	Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye. Leukemia and Lymphoma, 2021, 62, 1544-1553.	1.3	4
59	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia, 2021, 35, 1428-1437.	7.2	8
60	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving postâ€autologous stem cell transplantation lenalidomide maintenance therapy. American Journal of Hematology, 2021, 96, E157-E162.	4.1	12
61	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). Blood Cancer Journal, 2021, 11, 26.	6.2	10
62	Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Neurology and Therapy, 2021, 10, 375-389.	3.2	34
63	Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Advances, 2021, 5, 1029-1036.	5.2	9
64	Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clinic Proceedings, 2021, 96, 377-387.	3.0	12
65	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. Mayo Clinic Proceedings, 2021, 96, 677-687.	3.0	16
66	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer Journal, 2021, 11, 50.	6.2	25
67	Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma. Blood Advances, 2021, 5, 1797-1804.	5.2	26
68	Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation. Kidney International Reports, 2021, 6, 857-864.	0.8	5
69	Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal, 2021, 11, 63.	6.2	11
70	IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis. Blood Advances, 2021, 5, 2101-2105.	5.2	7
71	Autologous stem cell transplantation in the age of ANDROMEDA. British Journal of Haematology, 2021, 193, 865-866.	2.5	3
72	ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet Journal of Rare Diseases, 2021, 16, 204.	2.7	11

#	Article	IF	Citations
73	Prognostic impact of depth of response in WaldenstrÃ¶m macroglobulinemia patients treated with fixed duration chemoimmunotherapy.. Journal of Clinical Oncology, 2021, 39, 8049-8049.	1.6	1
74	Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. Blood Cancer Journal, 2021, 11, 90.	6.2	27
75	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. Leukemia, 2021, 35, 3604-3607.	7.2	8
76	The Clinical Impact of Proteomics in Amyloid Typing. Mayo Clinic Proceedings, 2021, 96, 1122-1127.	3.0	9
77	Clinical activity of systemic VSV-IFNÎ²-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.. Journal of Clinical Oncology, 2021, 39, 2500-2500.	1.6	3
78	Assessment of fixedâ€duration therapies for treatmentâ€naÃ¯ve <scp>WaldenstrÃ¶m</scp> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	4.1	12
79	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clinic Proceedings, 2021, 96, 1546-1577.	3.0	32
80	66-Year-Old Man With Recurrent Hypotension and Flank Pain. Mayo Clinic Proceedings, 2021, 96, 1622-1627.	3.0	0
81	Belantamab mafodotin detection by MASS-FIX and immunofixation. Clinical Chemistry and Laboratory Medicine, 2021, 59, e430-e433.	2.3	1
82	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 451-460.e2.	0.4	9
83	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. Transplantation and Cellular Therapy, 2021, 27, 589.e1-589.e6.	1.2	3
84	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Advances, 2021, 5, 2753-2759.	5.2	13
85	Should high risk smoldering myeloma be treated outside a clinical trial: NO. Leukemia and Lymphoma, 2021, 62, 2565-2567.	1.3	3
86	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. Leukemia and Lymphoma, 2021, 62, 3011-3018.	1.3	2
87	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. American Journal of Hematology, 2021, 96, 1131-1136.	4.1	21
88	Disease outcomes and biomarkers of progression in smouldering WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	2.5	12
89	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). Blood Cancer Journal, 2021, 11, 158.	6.2	9
90	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. Transplantation and Cellular Therapy, 2021, 27, 770.e1-770.e7.	1.2	6

#	Article	IF	Citations
91	Comparison of the current renal staging, progression and response criteria to predict renal survival in <scp>AL</scp> amyloidosis using a <scp>Mayo</scp> cohort. American Journal of Hematology, 2021, 96, 446-454.	4.1	8
92	WaldenstrÃ¶m macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2021, 96, 258-269.	4.1	49
93	Prognostic significance of acquired 1q22 gain in multiple myeloma. American Journal of Hematology, 2021, , .	4.1	6
94	The importance of immunoparesis in multiple myeloma. Leukemia and Lymphoma, 2021, 62, 769-770.	1.3	3
95	Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. Transplantation, 2021, 105, 1615-1624.	1.0	0
96	Birtamimab in Patients with Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory Affirm-AL Phase 3 Study Design. Blood, 2021, 138, 2754-2754.	1.4	4
97	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. Blood, 2021, 138, 1639-1639.	1.4	3
98	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. Blood, 2021, 138, 2707-2707.	1.4	0
99	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNÎ²-NIS). Blood, 2021, 138, 1333-1333.	1.4	0
100	Prognostic Role of IL-6 in POEMS Syndrome. Blood, 2021, 138, 2700-2700.	1.4	0
101	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio â‰¥100. Blood, 2021, 138, 1617-1617.	1.4	0
102	Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. Blood, 2021, 138, 2720-2720.	1.4	4
103	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. Blood, 2021, 138, 819-819.	1.4	1
104	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. Blood, 2021, 138, 3805-3805.	1.4	0
105	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer Journal, 2021, 11, 186.	6.2	8
106	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. Blood, 2021, 138, 3760-3760.	1.4	1
107	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. Blood, 2021, 138, 3773-3773.	1.4	0
108	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. Blood, 2021, 138, 2721-2721.	1.4	5

#	Article	IF	Citations
109	Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma. Blood, 2021, 138, 2711-2711.	1.4	2
110	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma-Pivotal Role of Cytogenetic Changes. Blood, 2021, 138, 3761-3761.	1.4	0
111	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. Blood, 2021, 138, 1632-1632.	1.4	0
112	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. Blood, 2021, 138, 3774-3774.	1.4	1
113	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. Blood, 2021, 138, 1619-1619.	1.4	0
114	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. Blood, 2021, 138, 543-543.	1.4	0
115	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. Blood, 2021, 138, 1630-1630.	1.4	0
116	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. Blood, 2021, 138, 568-568.	1.4	4
117	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2021, 138, 119-119.	1.4	0
118	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. Blood, 2021, 138, 2650-2650.	1.4	0
119	44-Year-Old Man With Anemia, Thrombocytopenia, and Acute Kidney Injury. Mayo Clinic Proceedings, 2021, , .	3.0	0
120	P-022: Survival benefit observed with Birtamimab in Mayo Stage IV AL amyloidosis supports initiation of confirmatory AFFIRM-AL phase 3 study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S51.	0.4	5
121	â€œReal-lifeâ€•data of the efficacy and safety of belantamab mafodotin in relapsed multiple myelomaâ€”the Mayo Clinic experience. Blood Cancer Journal, 2021, 11, 196.	6.2	28
122	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 13-16.	3.0	25
123	The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors. Acta Haematologica, 2020, 143, 118-123.	1.4	14
124	Management of induction failures in newly diagnosed transplant-eligible multiple myeloma. Leukemia and Lymphoma, 2020, 61, 1-3.	1.3	1
125	New developments in diagnosis, risk assessment and management in systemic amyloidosis. Blood Reviews, 2020, 40, 100636.	5.7	28
126	Ibrutinib monotherapy outside of clinical trial setting in WaldenstrÃ¶m macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	2.5	41

#	Article	IF	Citations
127	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. American Journal of Hematology, 2020, 95, E8-E10.	4.1	10
128	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American Journal of Hematology, 2020, 95, 4-9.	4.1	14
129	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 53-56.	0.4	8
130	Enhancing the Râ€ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. American Journal of Hematology, 2020, 95, 310-315.	4.1	37
131	Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. Journal of Neurology, 2020, 267, 1070-1079.	3.6	20
132	Implications and outcomes of MRDâ€negative multiple myeloma patients with immunofixation positivity. American Journal of Hematology, 2020, 95, E60-E62.	4.1	4
133	Impact of MYD88^{L265P} mutation status on histological transformation of WaldenstrÃ¶m Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	4.1	33
134	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020, 34, 1373-1382.	7.2	40
135	Revisiting complete response in light chain amyloidosis. Leukemia, 2020, 34, 1472-1475.	7.2	15
136	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia, 2020, 34, 1135-1143.	7.2	29
137	Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Reviews, 2020, 41, 100648.	5.7	267
138	Colon perforation in multiple myeloma patients â€“ A complication of highâ€dose steroid treatment. Cancer Medicine, 2020, 9, 8895-8901.	2.8	3
139	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 6581-6588.	7.0	32
140	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer Journal, 2020, 10, 95.	6.2	3
141	Predictors of short-term survival in WaldenstrÃ¶m Macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 2975-2979.	1.3	2
142	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. American Journal of Hematology, 2020, 95, 1280-1287.	4.1	17
143	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney International, 2020, 98, 1407-1418.	5.2	8
144	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Advances, 2020, 4, 3509-3519.	5.2	58

#	Article	IF	Citations
145	Worldwide Perspectives of Amyloidosis. Acta Haematologica, 2020, 143, 301-303.	1.4	2
146	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer Journal, 2020, 10, 82.	6.2	59
147	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, andÂmanaging kidney cancer. Kidney International, 2020, 98, 1108-1119.	5.2	26
148	Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. Mayo Clinic Proceedings, 2020, 95, 1852-1864.	3.0	105
149	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 2020, 21, 198.	2.9	60
150	Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. Blood Cancer Journal, 2020, 10, 87.	6.2	13
151	Acute Liver Rejection in a Multiple Myeloma Patient Treated with Lenalidomide. Case Reports in Transplantation, 2020, 2020, 1-4.	0.3	2
152	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer Journal, 2020, 10, 124.	6.2	12
153	Stem Cell Mobilization and Autologous Transplant for Immunoglobulin Light-Chain Amyloidosis. Hematology/Oncology Clinics of North America, 2020, 34, 1133-1144.	2.2	7
154	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplantation, 2020, 55, 2132-2137.	2.4	8
155	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1402-1405.	2.0	4
156	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. Blood Cancer Journal, 2020, 10, 52.	6.2	8
157	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer Journal, 2020, 10, 55.	6.2	36
158	Exhausted and outnumbered: CD4+ T cells in the myeloma battlefield. Leukemia and Lymphoma, 2020, 61, 1777-1779.	1.3	1
159	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplantation, 2020, 55, 1297-1304.	2.4	5
160	Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management. Current Oncology Reports, 2020, 22, 66.	4.0	59
161	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a â€˜graft versus hostâ€™-like syndrome and poor outcomes. Bone Marrow Transplantation, 2020, 55, 1879-1881.	2.4	1
162	Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement. Leukemia and Lymphoma, 2020, 61, 1752-1755.	1.3	5

#	Article	IF	Citations
163	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. American Journal of Hematology, 2020, 95, 637-642.	4.1	12
164	Systemic Amyloidosis Recognition, Prognosis, and Therapy. JAMA - Journal of the American Medical Association, 2020, 324, 79.	7.4	152
165	TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 250-253.	3.0	19
166	Characteristics of late transplantâ€associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2020, 95, 1170-1179.	4.1	19
167	V122I Transthyretin Cardiomyopathy. Journal of the American College of Cardiology, 2020, 76, 93-95.	2.8	3
168	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. Blood Cancer Journal, 2020, 10, 20.	6.2	26
169	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. Blood Cancer Journal, 2020, 10, 4.	6.2	18
170	Non-transplant eligible multiple myeloma: deciphering optimal first line regimens. Leukemia and Lymphoma, 2020, 61, 504-506.	1.3	0
171	Waldenstrom's macroglobulinemia in the era of immunotherapy. Leukemia and Lymphoma, 2020, 61, 1292-1304.	1.3	1
172	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. American Journal of Hematology, 2020, 95, 497-502.	4.1	35
173	Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. American Journal of Hematology, 2020, 95, E222-E225.	4.1	15
174	Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. American Journal of Hematology, 2020, 95, 848-860.	4.1	102
175	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 596-601.	0.4	15
176	When to Suspect a Diagnosis of Amyloidosis. Acta Haematologica, 2020, 143, 304-311.	1.4	41
177	Multiple Myeloma in the Time of COVID-19. Acta Haematologica, 2020, 143, 410-416.	1.4	49
178	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. Blood Advances, 2020, 4, 322-326.	5.2	8
179	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer Journal, 2020, 10, 41.	6.2	24
180	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. Blood, 2020, 136, 52-53.	1.4	4

#	Article	IF	Citations
181	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. Blood, 2020, 136, 48-49.	1.4	2
182	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 36-37.	1.4	4
183	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 30-31.	1.4	4
184	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2020, 136, 7-8.	1.4	1
185	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). Blood, 2020, 136, 12-13.	1.4	3
186	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. Blood, 2020, 136, 22-23.	1.4	1
187	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. Blood, 2020, 136, 27-28.	1.4	0
188	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. Blood, 2020, 136, 9-10.	1.4	0
189	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. Blood, 2020, 136, 44-45.	1.4	0
190	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. Blood, 2020, 136, 15-16.	1.4	0
191	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. Blood, 2020, 136, 14-15.	1.4	0
192	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. Blood, 2020, 136, 6-7.	1.4	0
193	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. Blood, 2020, 136, 21-22.	1.4	0
194	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 21-22.	1.4	0
195	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged â‰¥ 75 Treated with Novel Agents. Blood, 2020, 136, 12-13.	1.4	0
196	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. Blood, 2020, 136, 31-32.	1.4	1
197	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. Blood, 2020, 136, 37-38.	1.4	0
198	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. Blood, 2020, 136, 1-2.	1.4	0

#	Article	IF	Citations
199	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Blood, 2020, 136, 41-42.	1.4	0
200	WaldenstrÃ¶m Macroglobulinemia in the Very Elderly (â‰¥75 years):Clinical Characteristics and Outcomes. Blood, 2020, 136, 44-45.	1.4	8
201	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. American Journal of Hematology, 2019, 94, 306-311.	4.1	18
202	Daratumumab for the treatment of AL amyloidosis. Leukemia and Lymphoma, 2019, 60, 295-301.	1.3	27
203	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2019, 54, 587-594.	2.4	9
204	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. Bone Marrow Transplantation, 2019, 54, 442-447.	2.4	7
205	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplantation, 2019, 54, 353-367.	2.4	81
206	Advances in the treatment of hereditary transthyretin amyloidosis: A review. Brain and Behavior, 2019, 9, e01371.	2.2	71
207	Tenâ€year survivors in AL amyloidosis: characteristics and treatment pattern. British Journal of Haematology, 2019, 187, 588-594.	2.5	40
208	Therapy of Transthyretin Cardiomyopathy. Journal of the American College of Cardiology, 2019, 74, 296-298.	2.8	3
209	The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry. Kidney International, 2019, 96, 1005-1009.	5.2	30
210	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 101-102.	3.0	9
211	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. Blood Advances, 2019, 3, 1226-1229.	5.2	7
212	Characteristics of longâ€term survivors with multiple myeloma: A National Cancer Data Base analysis. Cancer, 2019, 125, 3574-3581.	4.1	7
213	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. American Journal of Hematology, 2019, 94, 1020-1026.	4.1	36
214	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. American Journal of Hematology, 2019, 94, 1066-1071.	4.1	14
215	Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. Expert Review of Clinical Pharmacology, 2019, 12, 701-711.	3.1	25
216	Joint Pain and Proteinuria. JAMA - Journal of the American Medical Association, 2019, 322, 1512.	7.4	1

#	Article	IF	Citations
217	Comparative analysis of staging systems in AL amyloidosis. Leukemia, 2019, 33, 811-814.	7.2	22
218	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. American Journal of Hematology, 2019, 94, E117-E120.	4.1	13
219	Risk adapted post-transplant maintenance in multiple myeloma. Expert Review of Hematology, 2019, 12, 107-118.	2.2	7
220	The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and of renal significance. Nephrology Dialysis Transplantation, 2019, 34, 1440-1452.	0.7	10
221	Magnetic Resonance Elastography of Liver in Light Chain Amyloidosis. Journal of Clinical Medicine, 2019, 8, 739.	2.4	11
222	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2019, 54, 2039-2050.	2.4	9
223	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. Leukemia and Lymphoma, 2019, 60, 2960-2967.	1.3	4
224	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. Biology of Blood and Marrow Transplantation, 2019, 25, 1520-1525.	2.0	9
225	Burden of hereditary transthyretin amyloidosis on quality of life. Muscle and Nerve, 2019, 60, 169-175.	2.2	39
226	Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin. Journal of Clinical Oncology, 2019, 37, 171-173.	1.6	27
227	Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. British Journal of Haematology, 2019, 185, 701-707.	2.5	17
228	The colorful landscape of multiple myeloma. Leukemia and Lymphoma, 2019, 60, 2099-2100.	1.3	1
229	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	6.2	38
230	Two types of amyloidosis presenting in a single patient: a case series. Blood Cancer Journal, 2019, 9, 30.	6.2	48
231	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. Bone Marrow Transplantation, 2019, 54, 1775-1779.	2.4	9
232	Multiple myeloma and kidney transplantation: the beginning of a new era. CKJ: Clinical Kidney Journal, 2019, 12, 213-215.	2.9	6
233	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. American Journal of Hematology, 2019, 94, 751-756.	4.1	15
234	Substratification of patients with newly diagnosed standardâ€risk multiple myeloma. British Journal of Haematology, 2019, 185, 254-260.	2.5	12

#	Article	IF	Citations
235	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia, 2019, 33, 1268-1272.	7.2	7
236	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. American Journal of Hematology, 2019, 94, E141-E143.	4.1	17
237	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia, 2019, 33, 1273-1277.	7.2	12
238	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometryâ€"Verified Typing. Mayo Clinic Proceedings, 2019, 94, 472-483.	3.0	59
239	Impact of acquired del(17p) in multiple myeloma. Blood Advances, 2019, 3, 1930-1938.	5.2	41
240	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. Blood Advances, 2019, 3, 744-750.	5.2	28
241	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiâ€parametric flow cytometry method. American Journal of Hematology, 2019, 94, 424-430.	4.1	11
242	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2019, 25, e108-e111.	2.0	20
243	Current role of high dose chemotherapy in the management of multiple myeloma. Leukemia and Lymphoma, 2019, 60, 1349-1351.	1.3	0
244	Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. Blood, 2019, 133, 763-766.	1.4	27
245	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1077-1081.	2.4	7
246	Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis. Acta Haematologica, 2019, 141, 93-106.	1.4	74
247	Primary systemic amyloidosis in patients with WaldenstrÃ¶m macroglobulinemia. Leukemia, 2019, 33, 790-794.	7.2	28
248	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia, 2019, 33, 730-738.	7.2	20
249	WaldenstrÃ¶m macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2019, 94, 266-276.	4.1	68
250	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia, 2019, 33, 527-531.	7.2	36
251	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia, 2019, 33, 531-536.	7.2	72
252	Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease. Blood, 2019, 134, 3510-3510.	1.4	1

#	Article	IF	Citations
253	Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life. Blood, 2019, 134, 794-794.	1.4	14
254	Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. Blood, 2019, 134, 4560-4560.	1.4	1
255	Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients. Blood, 2019, 134, 3166-3166.	1.4	27
256	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2019, 134, 72-72.	1.4	2
257	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. Blood, 2019, 134, 4334-4334.	1.4	1
258	A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. Blood, 2019, 134, 1846-1846.	1.4	2
259	Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM). Blood, 2019, 134, 5764-5764.	1.4	8
260	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. Blood, 2019, 134, 4386-4386.	1.4	2
261	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. Blood, 2019, 134, 1905-1905.	1.4	2
262	Rituximab-based maintenance therapy in WaldenstrÃ¶m macroglobulinemia: A case control study.. Journal of Clinical Oncology, 2019, 37, 7559-7559.	1.6	8
263	Plasma Cell Disorders. , 2019, , 411-422.		0
264	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. Mayo Clinic Proceedings, 2019, 94, 455-464.	3.0	16
265	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. Blood, 2019, 134, 4505-4505.	1.4	0
266	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). Blood, 2019, 134, 5523-5523.	1.4	0
267	WaldenstrÃ¶m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. Blood, 2019, 134, 1532-1532.	1.4	0
268	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 4396-4396.	1.4	0
269	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. Blood, 2019, 134, 3080-3080.	1.4	0
270	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. Blood, 2019, 134, 2774-2774.	1.4	0

#	Article	IF	Citations
271	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5833-5833.	1.4	0
272	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. Blood, 2019, 134, 1904-1904.	1.4	0
273	Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis. Blood, 2019, 134, 1770-1770.	1.4	0
274	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. Blood, 2019, 134, 5532-5532.	1.4	0
275	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. Blood, 2019, 134, 3171-3171.	1.4	1
276	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. Blood, 2019, 134, 1800-1800.	1.4	1
277	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 2197-2197.	1.4	0
278	Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. Blood, 2019, 134, 2013-2013.	1.4	0
279	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. Blood, 2019, 134, 5490-5490.	1.4	1
280	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia, 2018, 32, 1421-1426.	7.2	8
281	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia, 2018, 32, 2240-2249.	7.2	64
282	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica, 2018, 103, 1229-1234.	3.5	10
283	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 889-894.	4.1	14
284	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 2127-2132.	2.0	21
285	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with WaldenstrÃ¶m macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	1.8	71
286	Multiple myeloma â€“ a cure within reach. Leukemia and Lymphoma, 2018, 59, 2521-2523.	1.3	4
287	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia, 2018, 32, 1811-1815.	7.2	28
288	The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. Leukemia, 2018, 32, 1243-1246.	7.2	12

#	Article	IF	Citations
289	Fitting mSMART Into the Current Clinical Management of WaldenstrÃ¶m Macroglobulinemiaâ€"Reply. JAMA Oncology, 2018, 4, 745.	7.1	1
290	Testicular plasmacytoma: unique location or circumstantial presentation?. Leukemia and Lymphoma, 2018, 59, 1769-1771.	1.3	3
291	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplantation, 2018, 53, 326-333.	2.4	4
292	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. Mayo Clinic Proceedings, 2018, 93, 56-58.	3.0	16
293	Reply to Castillo et al.. American Journal of Hematology, 2018, 93, E71-E73.	4.1	3
294	WaldenstrÃ¶m macroglobulinemia treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 40.	6.2	17
295	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. British Journal of Haematology, 2018, 182, 71-77.	2.5	15
296	Unravelling hypothyroidism in <scp>AL</scp> amyloidosis: Authors' reply. Journal of Internal Medicine, 2018, 283, 108-108.	6.0	0
297	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 86-92.	3.0	57
298	Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients. , 2018, , 551-571.		0
299	Will we be able to afford a cure in multiple myeloma?. Leukemia and Lymphoma, 2018, 59, 1-2.	1.3	10
300	Diagnosis and management of smoldering multiple myeloma: the razorâ€™s edge between clonality and cancer. Leukemia and Lymphoma, 2018, 59, 288-299.	1.3	10
301	Natural history of t(11;14) multiple myeloma. Leukemia, 2018, 32, 131-138.	7.2	67
302	OCULAR MANIFESTATIONS OF SYSTEMIC AMYLOIDOSIS. Retina, 2018, 38, 1371-1376.	1.7	31
303	Efficacy of VDT PACEâ€like regimens in treatment of relapsed/refractory multiple myeloma. American Journal of Hematology, 2018, 93, 179-186.	4.1	49
304	MYD88 mutation status does not impact overall survival in WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2018, 93, 187-194.	4.1	57
305	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). American Journal of Hematology, 2018, 93, 17-22.	4.1	11
306	Pomalidomideâ€"dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. Leukemia, 2018, 32, 719-728.	7.2	13

#	Article	IF	Citations
307	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia, 2018, 32, 712-718.	7.2	27
308	Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia, 2018, 32, 729-735.	7.2	44
309	External beam radiation therapy for amyloidosis of the urinary bladder. Practical Radiation Oncology, 2018, 8, 25-27.	2.1	10
310	Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia, 2018, 32, 252-262.	7.2	234
311	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 155-161.	2.4	8
312	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. Journal of Clinical Oncology, 2018, 36, 1323-1329.	1.6	100
313	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. Blood Cancer Journal, 2018, 8, 106.	6.2	16
314	Venetoclax for the treatment of multiple myeloma. Expert Review of Hematology, 2018, 11, 915-920.	2.2	27
315	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer Journal, 2018, 8, 116.	6.2	64
316	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer Journal, 2018, 8, 125.	6.2	29
317	Systemic immunoglobulin light chain amyloidosis. Nature Reviews Disease Primers, 2018, 4, 38.	30.5	350
318	Utility and prognostic value of ¹⁸Fâ€FDG positron emission tomographyâ€computed tomography scans in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 1518-1523.	4.1	19
319	Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 180-188.	3.0	20
320	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Advances, 2018, 2, 769-776.	5.2	23
321	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Advances, 2018, 2, 3149-3154.	5.2	23
322	Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 44.	6.2	84
323	Defining Lymphoplasmacytic Lymphoma. American Journal of Clinical Pathology, 2018, 150, 168-176.	0.7	5
324	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2018, 24, 2360-2364.	2.0	14

#	Article	IF	Citations
325	Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 2018, 379, 22-31.	27.0	1,000
326	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biology of Blood and Marrow Transplantation, 2018, 24, 2157-2159.	2.0	8
327	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer Journal, 2018, 8, 70.	6.2	18
328	Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. American Journal of Hematology, 2018, 93, 1169-1180.	4.1	103
329	Immunoglobulin Light Chain Amyloidosis (Primary Amyloidosis). , 2018, , 1432-1443.		2
330	Serum free light chain measurements to reduce 24â€h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. American Journal of Hematology, 2018, 93, 1207-1210.	4.1	3
331	Clinical characteristics and treatment outcomes in IgE multiple myeloma: A caseâ€control study. American Journal of Hematology, 2018, 93, E238-E241.	4.1	6
332	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e006588.	2.6	51
333	Immunoglobulin Light Chain Amyloidosis (AL). , 2018, , 651-672.		1
334	Predictors of symptomatic hyperviscosity in WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2018, 93, 1384-1393.	4.1	24
335	Acute hyperviscosity: syndromes and management. Blood, 2018, 132, 1379-1385.	1.4	79
336	Kidney Involvement of Patients with WaldenstrÃ¶m Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1037-1046.	4.5	46
337	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	6.2	171
338	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 304-304.	1.4	10
339	Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis. Blood, 2018, 132, 498-498.	1.4	2
340	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. Blood, 2018, 132, 4460-4460.	1.4	1
341	Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial. Blood, 2018, 132, 4803-4803.	1.4	1
342	Inhibition of C3 with APL-2 Results in Normalisation of Markers of Intravascular and Extravascular Hemolysis in Patients with Autoimmune Hemolytic Anemia (AIHA). Blood, 2018, 132, 3623-3623.	1.4	21

#	Article	IF	Citations
343	Impact of Inotersen on Functioning and Activities of Daily Living for Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial. Blood, 2018, 132, 4812-4812.	1.4	1
344	Daratumumab-based therapies in patients with AL amyloidosis.. Journal of Clinical Oncology, 2018, 36, 8053-8053.	1.6	2
345	Long-Term Survivorship with Active Multiple Myeloma. Blood, 2018, 132, 1912-1912.	1.4	0
346	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	1.4	0
347	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 622-622.	1.4	1
348	Depth of Response in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 4141-4141.	1.4	2
349	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3159-3159.	1.4	0
350	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3158-3158.	1.4	0
351	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	1.4	0
352	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood, 2018, 132, 2147-2147.	1.4	0
353	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	1.4	0
354	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	1.4	1
355	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. Blood, 2018, 132, 4613-4613.	1.4	0
356	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	1.4	0
357	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). Blood, 2018, 132, 4502-4502.	1.4	0
358	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 1902-1902.	1.4	1
359	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. Blood, 2018, 132, 5594-5594.	1.4	0
360	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. Blood, 2018, 132, 3227-3227.	1.4	0

#	Article	IF	Citations
361	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. Blood, 2018, 132, 5610-5610.	1.4	0
362	Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). Blood, 2018, 132, 4138-4138.	1.4	0
363	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268.	1.4	0
364	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. Blood, 2018, 132, 3436-3436.	1.4	0
365	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	1.4	1
366	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2018, 132, 4615-4615.	1.4	0
367	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. Blood, 2018, 132, 3160-3160.	1.4	2
368	Prognosis of Patients with WaldenstrÃ¶m Macroglobulinemia: A Simplified Model. Blood, 2018, 132, 4152-4152.	1.4	1
369	Patient-Reported Outcome Driven Case Management System for Hematology â€" a Prospective Study. Blood, 2018, 132, 719-719.	1.4	1
370	Novel Type of Renal Amyloidosis Derived from Apolipoprotein-CII. Journal of the American Society of Nephrology: JASN, 2017, 28, 439-445.	6.1	57
371	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Leukemia, 2017, 31, 92-99.	7.2	30
372	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. Leukemia and Lymphoma, 2017, 58, 308-315.	1.3	16
373	Assessing mNIS+7_{Ionis} and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial. Muscle and Nerve, 2017, 56, 901-911.	2.2	42
374	+1q: amplifying the bad genes in myeloma. Leukemia and Lymphoma, 2017, 58, 1771-1773.	1.3	6
375	WaldenstrÃ¶m macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2017, 92, 209-217.	4.1	42
376	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. Biology of Blood and Marrow Transplantation, 2017, 23, 598-605.	2.0	47
377	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Annals of Medicine, 2017, 49, 545-551.	3.8	45
378	Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer Journal, 2017, 7, e528-e528.	6.2	39

#	Article	IF	Citations
379	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. American Journal of Hematology, 2017, 92, 435-440.	4.1	16
380	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood, 2017, 129, 82-87.	1.4	50
381	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood, 2017, 129, 2111-2119.	1.4	249
382	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. American Journal of Hematology, 2017, 92, E164-E166.	4.1	5
383	Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. Bone Marrow Transplantation, 2017, 52, 1126-1132.	2.4	30
384	Management of macroglobulinaemia. British Journal of Haematology, 2017, 177, 669-671.	2.5	1
385	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 40-41.	3.0	4
386	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 44-45.	3.0	1
387	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. Journal of Internal Medicine, 2017, 281, 611-619.	6.0	15
388	Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia, 2017, 31, 2791-2798.	7.2	120
389	Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart, 2017, 103, 1065-1072.	2.9	148
390	Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia, 2017, 31, 1562-1569.	7.2	92
391	Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. Blood Cancer Journal, 2017, 7, e569-e569.	6.2	8
392	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. American Journal of Hematology, 2017, 92, E507-E512.	4.1	5
393	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. American Journal of Hematology, 2017, 92, 668-673.	4.1	75
394	Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2017, 92, 578-598.	3.0	115
395	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. American Journal of Hematology, 2017, 92, 549-554.	4.1	24
396	Stem cell transplantation for immunoglobulin light chain amyloidosis. Current Problems in Cancer, 2017, 41, 129-137.	2.0	9

#	Article	IF	Citations
397	How I treat cryoglobulinemia. Blood, 2017, 129, 289-298.	1.4	122
398	Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood, 2017, 129, 299-306.	1.4	99
399	Diagnosis and Management of WaldenstrÃ¶m Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	7.1	110
400	Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation. Progress in Transplantation, 2017, 27, 246-250.	0.7	21
401	First report of MYD88^{L265P} somatic mutation in IgM-associated light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 42-43.	3.0	10
402	Delineation of the timing of second-line therapy postâ€“autologous stem cell transplant in patients with AL amyloidosis. Blood, 2017, 130, 1578-1584.	1.4	21
403	Attitudes about when and how to treat patients with AL amyloidosis: an international survey. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 213-216.	3.0	31
404	Ocular Manifestations of Familial Transthyretin Amyloidosis. American Journal of Ophthalmology, 2017, 183, 156-162.	3.3	64
405	Restrictive Cardiomyopathy. Circulation Research, 2017, 121, 819-837.	4.5	219
406	Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer Journal, 2017, 7, e600-e600.	6.2	57
407	A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. Bone Marrow Transplantation, 2017, 52, 1372-1377.	2.4	13
408	Elevation of serum lactate dehydrogenase in <scp>AL</scp> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. British Journal of Haematology, 2017, 178, 888-895.	2.5	15
409	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. Haematologica, 2017, 102, 1439-1445.	3.5	29
410	Clinical trials evaluating potential therapies for light chain (AL) amyloidosis. Expert Opinion on Orphan Drugs, 2017, 5, 655-663.	0.8	0
411	Dexamethasone, rituximab and cyclophosphamide for relapsedÂand/or refractory and treatmentâ€naÃ¯ve patients with Waldenstrom macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	2.5	25
412	Efficacy of daratumumabâ€based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. American Journal of Hematology, 2017, 92, 1146-1155.	4.1	25
413	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 183-188.	3.0	4
414	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood, 2017, 130, 1198-1204.	1.4	54

#	Article	IF	Citations
415	Acquired transthyretin amyloidosis after domino liver transplant: Phenotypic correlation, implication of liver retransplantation. Journal of the Neurological Sciences, 2017, 379, 192-197.	0.6	9
416	High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges. Leukemia and Lymphoma, 2017, 58, 1283-1296.	1.3	6
417	Secondary malignancies in patients with multiple myeloma, WaldenstrÃ¶m macroglobulinemia and monoclonal gammopathy of undetermined significance. Leukemia and Lymphoma, 2017, 58, 773-780.	1.3	24
418	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplantation, 2017, 52, 34-40.	2.4	30
419	Natural history of amyloidosis isolated to fat and bone marrow aspirate. British Journal of Haematology, 2017, 179, 170-172.	2.5	10
420	Betaâ€blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. American Journal of Hematology, 2017, 92, 50-55.	4.1	41
421	Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia, 2017, 31, 130-135.	7.2	63
422	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2017, 92, 908-917.	3.0	72
423	Factors predicting organ response in light chain amyloidosis (AL).. Journal of Clinical Oncology, 2017, 35, 8048-8048.	1.6	1
424	Importance of FISH genetics in light chain amyloidosis. Oncotarget, 2017, 8, 81735-81736.	1.8	7
425	Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. American Journal of Managed Care, 2017, 23, S107-S112.	1.1	42
426	Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. Blood Coagulation and Fibrinolysis, 2016, 27, 101-108.	1.0	9
427	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin lightâ€chain amyloidosis. Cancer, 2016, 122, 2197-2205.	4.1	37
428	Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplantation, 2016, 51, 1449-1455.	2.4	51
429	Induction therapy preâ€autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. American Journal of Hematology, 2016, 91, 984-988.	4.1	45
430	Panobinostat in multiple myeloma. Lancet Haematology,the, 2016, 3, e552-e553.	4.6	5
431	Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer Journal, 2016, 6, e454-e454.	6.2	56
432	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer Journal, 2016, 6, e512-e512.	6.2	38

#	Article	IF	Citations
433	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica, 2016, 101, 1102-1109.	3.5	9
434	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leukemia Research, 2016, 44, 32-39.	0.8	22
435	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 447-452.	0.4	24
436	Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia, 2016, 30, 2208-2213.	7.2	87
437	Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. Bone Marrow Transplantation, 2016, 51, 1156-1158.	2.4	17
438	Lenalidomide â€“ the new melphalan?. Leukemia and Lymphoma, 2016, 57, 1749-1750.	1.3	0
439	Treatment recommendations from the Eighth International Workshop on WaldenstrÃ¶mâ€™s Macroglobulinemia. Blood, 2016, 128, 1321-1328.	1.4	161
440	Myelomatous Involvement of the Central Nervous System. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 644-654.	0.4	38
441	Systemic Immunoglobulin Light Chain Amyloidosisâ€“Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clinic Proceedings, 2016, 91, 1354-1361.	3.0	43
442	Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia, 2016, 30, 1979-1986.	7.2	73
443	Newer Therapies for Amyloid Cardiomyopathy. Current Heart Failure Reports, 2016, 13, 237-246.	3.3	13
444	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. American Journal of Hematology, 2016, 91, 1123-1128.	4.1	76
445	Longâ€term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. American Journal of Hematology, 2016, 91, 585-589.	4.1	57
446	Natural History of Wild-Type TransthyretinÂCardiac Amyloidosis andÂRisk Stratification Using a NovelÂStaging System. Journal of the American College of Cardiology, 2016, 68, 1014-1020.	2.8	460
447	Nâ€terminal fragment of the typeâ€B natriuretic peptide (NTâ€proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 1129-1134.	4.1	71
448	Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. American Journal of Hematology, 2016, 91, 947-956.	4.1	100
449	Organ response in patients with AL amyloidosis treated with NEOD001, an amyloidâ€directed monoclonal antibody. American Journal of Hematology, 2016, 91, E506-E508.	4.1	26
450	First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. Blood, 2016, 127, 2936-2938.	1.4	17

#	Article	IF	Citations
451	Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox?. Annals of Neurology, 2016, 80, 401-411.	5.3	17
452	IAP antagonists induce anti-tumor immunity in multiple myeloma. Nature Medicine, 2016, 22, 1411-1420.	30.7	133
453	The role of stem cell transplantation in Waldenstrom's macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 229-240.	1.7	6
454	First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. Blood, 2016, 128, 1987-1989.	1.4	83
455	Clinical characteristics and outcomes in biclonal gammopathies. American Journal of Hematology, 2016, 91, 473-475.	4.1	30
456	Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy. Acta Haematologica, 2016, 135, 172-190.	1.4	57
457	Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. Leukemia, 2016, 30, 1079-1085.	7.2	32
458	A practical review on carfilzomib in multiple myeloma. European Journal of Haematology, 2016, 96, 564-577.	2.2	48
459	Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer Journal, 2016, 6, e401-e401.	6.2	30
460	First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of Clinical Oncology, 2016, 34, 1097-1103.	1.6	176
461	Life beyond bortezomib: increasing treatment options in refractory myeloma. Leukemia and Lymphoma, 2016, 57, 1251-1253.	1.3	0
462	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrology Dialysis Transplantation, 2016, 31, 1284-1289.	0.7	25
463	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leukemia and Lymphoma, 2016, 57, 2071-2076.	1.3	30
464	Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2016, 22, 796-801.	2.0	16
465	Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia, 2016, 30, 633-639.	7.2	57
466	Lymphoplasmacytic lymphoma: What we need to know. Leukemia and Lymphoma, 2016, 57, 991-992.	1.3	3
467	Utility of immunophenotyping of plasma cells in multiple myeloma. Leukemia and Lymphoma, 2016, 57, 252-253.	1.3	1
468	ANX005, an Inhibitory Antibody Against C1q, Blocks Complement Activation Triggered By Cold Agglutinins in Human Disease. Blood, 2016, 128, 1265-1265.	1.4	20

#	Article	IF	Citations
469	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 2082-2082.	1.4	1
470	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). Blood, 2016, 128, 2968-2968.	1.4	4
471	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.	1.4	2
472	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. Blood, 2016, 128, 3272-3272.	1.4	1
473	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. Blood, 2016, 128, 3317-3317.	1.4	3
474	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. Blood, 2016, 128, 3337-3337.	1.4	5
475	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. Blood, 2016, 128, 3444-3444.	1.4	1
476	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. Blood, 2016, 128, 4627-4627.	1.4	1
477	The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction. Blood, 2016, 128, 5690-5690.	1.4	5
478	NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study. Blood, 2016, 128, 644-644.	1.4	9
479	Organ Biomarker Responses in Patients with Light Chain Amyloidosis Treated with NEOD001 Are Independent of Previous Hematologic Response. Blood, 2016, 128, 647-647.	1.4	1
480	Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2016, 34, 8002-8002.	1.6	5
481	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).. Journal of Clinical Oncology, 2016, 34, 8004-8004.	1.6	3
482	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.. Journal of Clinical Oncology, 2016, 34, 8015-8015.	1.6	1
483	Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World Journal of Transplantation, 2016, 6, 380.	1.6	56
484	Cryoglobulins and Cryoglobulinemia. , 2016, , 633-645.		1
485	The impact of novel induction regimens on transplant outcome in newly diagnosed multiple myeloma after controlling for high-risk FISH cytogenetics.. Journal of Clinical Oncology, 2016, 34, 8033-8033.	1.6	0
486	Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2016, 34, 8017-8017.	1.6	0

#	Article	IF	Citations
487	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naÃ¯ve (TN) WaldenstrÃ¶m macroglobulinemia (WM).. Journal of Clinical Oncology, 2016, 34, 7552-7552.	1.6	1
488	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. Journal of Clinical Oncology, 2016, 34, 8062-8062.	1.6	0
489	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. Journal of Clinical Oncology, 2016, 34, 8016-8016.	1.6	0
490	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. Blood, 2016, 128, 3276-3276.	1.4	0
491	Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2960-2960.	1.4	15
492	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2016, 128, 5615-5615.	1.4	0
493	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. Blood, 2016, 128, 996-996.	1.4	0
494	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. Blood, 2016, 128, 3273-3273.	1.4	0
495	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. Blood, 2016, 128, 3251-3251.	1.4	0
496	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. Blood, 2016, 128, 1810-1810.	1.4	0
497	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. Blood, 2016, 128, 3306-3306.	1.4	0
498	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. Blood, 2016, 128, 1194-1194.	1.4	0
499	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. Blood, 2016, 128, 3269-3269.	1.4	0
500	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 3338-3338.	1.4	0
501	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. Blood, 2016, 128, 3255-3255.	1.4	0
502	Outcome of Very Young (â‰¤ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. Blood, 2016, 128, 5576-5576.	1.4	0
503	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. Blood, 2016, 128, 2187-2187.	1.4	0
504	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. Blood, 2016, 128, 2267-2267.	1.4	0

#	Article	IF	Citations
505	Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. American Journal of Hematology, 2015, 90, 1106-1110.	4.1	19
506	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. American Journal of Hematology, 2015, 90, 888-891.	4.1	18
507	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. American Journal of Hematology, 2015, 90, 981-985.	4.1	38
508	Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2015, 5, e296-e296.	6.2	90
509	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leukemia and Lymphoma, 2015, 56, 3357-3364.	1.3	36
510	WaldenstrÃ¶m macroglobulinemia: 2015 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2015, 90, 346-354.	4.1	36
511	When to recommend allogeneic transplant in multiple myeloma. Leukemia and Lymphoma, 2015, 56, 2512-2517.	1.3	9
512	Utility of the immunoglobulin free light chain assay for plasma cell disorders 2015. Leukemia and Lymphoma, 2015, 56, 2757-2758.	1.3	2
513	Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer Journal, 2015, 5, e364-e364.	6.2	81
514	Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. Blood Cancer Journal, 2015, 5, e363-e363.	6.2	36
515	Developing a clinical trial unit to advance research in an academic institution. Contemporary Clinical Trials, 2015, 45, 270-276.	1.8	26
516	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. American Journal of Hematology, 2015, 90, 181-186.	4.1	76
517	Advanced Skeletal Imaging Redefines the Management of Plasma Cell Disorders. Journal of Clinical Oncology, 2015, 33, 537-539.	1.6	5
518	Clinical course and prognosis of nonâ€secretory multiple myeloma. European Journal of Haematology, 2015, 95, 57-64.	2.2	50
519	Using Novel Agents and Stem Cell Transplantation to Optimally Manage Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2015, 21, 1339-1340.	2.0	1
520	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. Mayo Clinic Proceedings, 2015, 90, 587-596.	3.0	92
521	Treatment of Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2015, 90, 1054-1081.	3.0	106
522	Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 123-131.	3.0	83

#	Article	IF	Citations
523	Ibrutinib for the treatment of WaldenstrÃ¶m macroglobulinemia. Expert Review of Hematology, 2015, 8, 569-579.	2.2	14
524	Improving strategies for the diagnosis of cardiac amyloidosis. Expert Review of Cardiovascular Therapy, 2015, 13, 945-961.	1.5	6
525	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. Leukemia and Lymphoma, 2015, 56, 1723-1726.	1.3	19
526	Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 349-357.e2.	0.4	10
527	Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia, 2015, 29, 2033-2038.	7.2	25
528	Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplantation, 2015, 50, 1513-1518.	2.4	34
529	Emerging therapeutic options for WaldenstrÃ¶m macroglobulinemia/lymphoplasmacytic lymphoma. Expert Review of Anticancer Therapy, 2015, 15, 1143-1156.	2.4	5
530	Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer Journal, 2015, 5, e310-e310.	6.2	62
531	The role of bendamustine in the management of plasma cell myeloma. Leukemia and Lymphoma, 2015, 56, 1195-1196.	1.3	0
532	Phase II clinical trials for Waldenstromâ€™s macroglobulinemia. Expert Opinion on Orphan Drugs, 2015, 3, 537-547.	0.8	0
533	Soluble suppression of tumorigenicity 2 (s<scp>ST</scp>2), but not galactinâ€3, adds to prognostication in patients with systemic <scp>AL</scp> amyloidosis independent of <scp>NT</scp>â€pro<scp>BNP</scp> and troponin <scp>T</scp>. American Journal of Hematology, 2015, 90, 524-528.	4.1	31
534	Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer Journal, 2015, 5, e338-e338.	6.2	68
535	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Journal of Clinical Oncology, 2015, 33, 3741-3749.	1.6	163
536	Diagnosis, Prognosis, and Therapy ofÂTransthyretin Amyloidosis. Journal of the American College of Cardiology, 2015, 66, 2451-2466.	2.8	344
537	Making the Case to Study the Volume-Outcome Relationship in Hematologic Cancers. Mayo Clinic Proceedings, 2015, 90, 1393-1399.	3.0	11
538	Pathophysiology and treatment of cardiac amyloidosis. Nature Reviews Cardiology, 2015, 12, 91-102.	13.7	123
539	Frequencies and geographic distributions of genetic mutations in transthyretinâ€•and nonâ€transthyretinâ€•related familial amyloidosis. Clinical Genetics, 2015, 88, 396-400.	2.0	24
540	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). Blood, 2015, 126, 1774-1774.	1.4	6

#	Article	IF	Citations
541	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. Blood, 2015, 126, 1830-1830.	1.4	1
542	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. Blood, 2015, 126, 3050-3050.	1.4	8
543	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. Blood, 2015, 126, 3177-3177.	1.4	3
544	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. Blood, 2015, 126, 4197-4197.	1.4	5
545	VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia. Blood, 2015, 126, 703-703.	1.4	4
546	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). Blood, 2015, 126, 3292-3292.	1.4	0
547	Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. Blood, 2015, 126, 3039-3039.	1.4	0
548	AL Amyloidosis and Patient Reported Quality of Life. Blood, 2015, 126, 3317-3317.	1.4	0
549	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. Blood, 2015, 126, 4176-4176.	1.4	0
550	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. Blood, 2015, 126, 5303-5303.	1.4	0
551	The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Blood, 2015, 126, 3044-3044.	1.4	0
552	Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica, 2014, 99, 1239-1247.	3.5	140
553	Immunoglobulin light chain amyloidosis. Expert Review of Hematology, 2014, 7, 143-156.	2.2	98
554	Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. Bone Marrow Transplantation, 2014, 49, 201-205.	2.4	20
555	Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia, 2014, 28, 2060-2065.	7.2	109
556	Potential new risks of lenalidomide. Leukemia and Lymphoma, 2014, 55, 1962-1963.	1.3	0
557	Bortezomib-based combination regimens in myeloma: more is not necessarily better. Leukemia and Lymphoma, 2014, 55, 1439-1440.	1.3	0
558	Longâ€term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. American Journal of Hematology, 2014, 89, 237-242.	4.1	68

#	Article	IF	Citations
559	Costâ€effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. Clinical Transplantation, 2014, 28, 1084-1091.	1.6	21
560	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. American Journal of Hematology, 2014, 89, 1051-1054.	4.1	32
561	Recent advances in the diagnosis and management of cardiac amyloidosis. Future Cardiology, 2014, 10, 131-146.	1.2	11
562	High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart, 2014, 100, 383-388.	2.9	63
563	Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis. American Journal of Cardiology, 2014, 113, 1723-1727.	1.6	112
564	Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia, 2014, 28, 1122-1128.	7.2	1,128
565	Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma. Leukemia, 2014, 28, 455-457.	7.2	6
566	Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. American Journal of Hematology, 2014, 89, 1132-1140.	4.1	131
567	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. European Journal of Haematology, 2014, 92, 485-490.	2.2	23
568	Quantification of clonal circulating plasma cells in relapsed multiple myeloma. British Journal of Haematology, 2014, 167, 500-505.	2.5	81
569	Domino liver transplantation as a cause of acquired familial amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 136-137.	3.0	12
570	Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification. Biology of Blood and Marrow Transplantation, 2014, 20, 222-228.	2.0	36
571	Left Ventricular Amyloid Deposition inÂPatientsÂWith Heart Failure andÂPreservedÂEjection Fraction. JACC: Heart Failure, 2014, 2, 113-122.	4.1	309
572	Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. Mayo Clinic Proceedings, 2014, 89, 926-933.	3.0	240
573	How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood, 2014, 124, 882-890.	1.4	85
574	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood, 2014, 124, 907-912.	1.4	111
575	Treatment recommendations for patients with WaldenstrÃ¶m macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood, 2014, 124, 1404-1411.	1.4	138
576	WaldenstrÃ¶m macroglobulinaemia: the key questions. British Journal of Haematology, 2013, 162, 295-303.	2.5	7

#	Article	IF	Citations
577	Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. American Journal of Hematology, 2013, 88, 416-425.	4.1	74
578	Smoldering multiple myeloma requiring treatment: time for a new definition?. Blood, 2013, 122, 4172-4181.	1.4	70
579	Pomalidomide and myeloma meningitis. Leukemia and Lymphoma, 2013, 54, 681-682.	1.3	11
580	Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. American Journal of Hematology, 2013, 88, 375-378.	4.1	34
581	What is WaldenstrÃ¶m macroglobulinemia?. Leukemia and Lymphoma, 2013, 54, 2345-2346.	1.3	1
582	Cold agglutinin disease. Blood, 2013, 122, 1114-1121.	1.4	235
583	Response assessment in <scp>W</scp>aldenstrÃ¶m macroglobulinaemia: update from the <scp>VI</scp>th <scp>I</scp>nternational <scp>W</scp>orkshop. British Journal of Haematology, 2013, 160, 171-176.	2.5	226
584	Diagnosis and Therapy of Immunoglobulin Light Chain Amyloidosis (AL Amyloidosis). , 2013, , 729-750.		0
585	Left ventricular device implantation for advanced cardiac amyloidosis. Journal of Heart and Lung Transplantation, 2013, 32, 563-568.	0.6	65
586	Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization. Biology of Blood and Marrow Transplantation, 2013, 19, 87-93.	2.0	76
587	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clinic Proceedings, 2013, 88, 360-376.	3.0	440
588	Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1233-1237.	2.0	37
589	Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplantation, 2013, 48, 568-573.	2.4	59
590	WaldenstrÃ¶m macroglobulinemia: my way. Leukemia and Lymphoma, 2013, 54, 464-471.	1.3	11
591	Exploring the amyloid proteome in immunoglobulinâ€derived lymph node amyloidosis using laser microdissection/tandem mass spectrometry. American Journal of Hematology, 2013, 88, 577-580.	4.1	18
592	WaldenstrÃ¶m macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2013, 88, 703-711.	4.1	46
593	Genotype, echocardiography, and survival in familial transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 263-268.	3.0	28
594	A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?. Haematologica, 2013, 98, 988-992.	3.5	49

#	Article	IF	Citations
595	The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney International, 2013, 83, 463-470.	5.2	101
596	Salvage autologous stem cell transplant is an effective regimen for relapsed multiple myeloma. Leukemia and Lymphoma, 2013, 54, 2096-2097.	1.3	1
597	Chemoprevention for smoldering multiple myeloma: not ready for prime time. Leukemia and Lymphoma, 2013, 54, 2331-2332.	1.3	0
598	Long-term outcome of patients with mutiple myeloma-related advanced renal failure following auto-SCT. Bone Marrow Transplantation, 2013, 48, 1543-1547.	2.4	30
599	Thermal Stability Threshold for Amyloid Formation in Light Chain Amyloidosis. International Journal of Molecular Sciences, 2013, 14, 22604-22617.	4.1	24
600	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. Journal of Clinical Oncology, 2013, 31, 4319-4324.	1.6	193
601	Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplantation, 2013, 48, 557-561.	2.4	158
602	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 4529-4535.	1.6	147
603	A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia, 2013, 27, 220-225.	7.2	85
604	Implications of continued response after autologous stem cell transplantation for multiple myeloma. Blood, 2013, 122, 1746-1749.	1.4	21
605	Proteome Of Amyloidosis: Mayo Clinic Experience In 4139 Cases. Blood, 2013, 122, 1900-1900.	1.4	13
606	Survival Outcomes Of Very Young (<40 years) Myeloma Patients. Blood, 2013, 122, 2136-2136.	1.4	3
607	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. Blood, 2013, 122, 3095-3095.	1.4	1
608	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. Blood, 2013, 122, 3117-3117.	1.4	2
609	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. Blood, 2013, 122, 3119-3119.	1.4	3
610	Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. Blood, 2013, 122, 3210-3210.	1.4	7
611	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. Blood, 2013, 122, 407-407.	1.4	12
612	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. Blood, 2013, 122, 2151-2151.	1.4	9

#	Article	IF	Citations
613	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. Blood, 2013, 122, 1979-1979.	1.4	0
614	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3209-3209.	1.4	0
615	Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. Blood, 2013, 122, 754-754.	1.4	0
616	Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. Blood, 2013, 122, 1842-1842.	1.4	0
617	Mass Spectrometry-Based Proteomics Reveals Distinct Immunoglobulin Light Chain Variable Region Usage In Systemic Versus Localized AL Amyloidosis. Blood, 2013, 122, 3142-3142.	1.4	0
618	Shining a warm light on cryoglobulinemia. Oncology, 2013, 27, 1116, 1118.	0.5	0
619	Stem cell transplant for WaldenstrÃ¶m macroglobulinemia: an underutilized technique. Bone Marrow Transplantation, 2012, 47, 1147-1153.	2.4	24
620	Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. Journal of Clinical Oncology, 2012, 30, 989-995.	1.6	837
621	Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrology Dialysis Transplantation, 2012, 27, 1097-1101.	0.7	61
622	How to manage primary amyloidosis. Leukemia, 2012, 26, 191-198.	7.2	47
623	Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies. Leukemia, 2012, 26, 1119-1122.	7.2	15
624	Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood, 2012, 119, 5397-5404.	1.4	144
625	Managing light chain deposition disease. Leukemia and Lymphoma, 2012, 53, 183-184.	1.3	15
626	WaldenstrÃ¶m macroglobulinemia. Hematology, 2012, 17, s112-s116.	1.5	7
627	Immunoglobulin D amyloidosis: a distinct entity. Blood, 2012, 119, 44-48.	1.4	17
628	High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood, 2012, 119, 1117-1122.	1.4	78
629	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood, 2012, 119, 4860-4867.	1.4	119
630	Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood, 2012, 120, 56-62.	1.4	133

#	Article	IF	Citations
631	Baby, it's cold outside!. Blood, 2012, 119, 5943-5944.	1.4	4
632	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood, 2012, 119, 2100-2105.	1.4	218
633	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. Journal of Clinical Oncology, 2012, 30, 4541-4549.	1.6	735
634	What do I need to know about immunoglobulin light chain (AL) amyloidosis?. Blood Reviews, 2012, 26, 137-154.	5.7	106
635	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157.	7.2	664
636	WaldenstrÃ¶m Macroglobulinemia: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2012, 87, 503-510.	4.1	38
637	Trends and outcomes of modern staging of solitary plasmacytoma of bone. American Journal of Hematology, 2012, 87, 647-651.	4.1	69
638	Tenâ€year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer, 2012, 118, 6105-6109.	4.1	57
639	A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. British Journal of Haematology, 2012, 156, 326-333.	2.5	48
640	Evaluation of pretransplant factors predicting cardiac dysfunction following highâ€dose melphalan conditioning and autologous peripheral blood stem cell transplantation. European Journal of Haematology, 2012, 89, 228-235.	2.2	11
641	Early versus delayed autologous transplantation after immunomodulatory agentsâ€based induction therapy in patients with newly diagnosed multiple myeloma. Cancer, 2012, 118, 1585-1592.	4.1	106
642	Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma. American Journal of Hematology, 2012, 87, 1-4.	4.1	18
643	Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with lightâ€chain amyloidosis. American Journal of Hematology, 2012, 87, 51-54.	4.1	20
644	Immunoglobulin light chain amyloidosis: 2012 update on diagnosis, prognosis, and treatment. American Journal of Hematology, 2012, 87, 183-189.	4.1	1
645	Case vignettes and other brain teasers of monoclonal gammopathies. Hematology American Society of Hematology Education Program, 2012, 2012, 582-585.	2.5	4
646	Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant. Blood, 2012, 120, 1858-1858.	1.4	2
647	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients. Blood, 2012, 120, 201-201.	1.4	16
648	MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression.. Blood, 2012, 120, 2699-2699.	1.4	3

#	Article	IF	Citations
649	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. Blood, 2012, 120, 3138-3138.	1.4	26
650	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. Blood, 2012, 120, 3972-3972.	1.4	7
651	Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US). Blood, 2012, 120, 602-602.	1.4	1
652	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. Blood, 2012, 120, 946-946.	1.4	1
653	Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.. Blood, 2012, 120, 2973-2973.	1.4	16
654	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. Blood, 2012, 120, 448-448.	1.4	0
655	The Natural History of Cold Agglutinin Disease. Blood, 2012, 120, 5152-5152.	1.4	0
656	Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma â€“ Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials.. Blood, 2012, 120, 3165-3165.	1.4	1
657	Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis. Blood, 2012, 120, 599-599.	1.4	0
658	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2012, 120, 1988-1988.	1.4	0
659	Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials. Oncology, 2012, 26, 152-61.	0.5	11
660	Case vignettes and other brain teasers of monoclonal gammopathies. Hematology American Society of Hematology Education Program, 2012, 2012, 582-5.	2.5	5
661	Reducing neurotoxicity in the management of multiple myeloma. Leukemia and Lymphoma, 2011, 52, 2043-2044.	1.3	0
662	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood, 2011, 117, 4701-4705.	1.4	377
663	Stem cell transplant: an effective salvage therapy for multiple myeloma. Leukemia and Lymphoma, 2011, 52, 1413-1414.	1.3	5
664	The role of bisphosphonate therapy in the global management of multiple myeloma. Leukemia and Lymphoma, 2011, 52, 736-737.	1.3	1
665	Utility of Doppler Myocardial Imaging, Cardiac Biomarkers, and Clonal Immunoglobulin Genes to Assess Left Ventricular Performance and Stratify Risk Following Peripheral Blood Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis (AL). Journal of the American Society of Echocardiography, 2011, 24, 444-454.e2.	2.8	21
666	Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score. Mayo Clinic Proceedings, 2011, 86, 12-18.	3.0	164

#	Article	IF	Citations
667	IgM Amyloidosis: Clinical Features in Therapeutic Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 146-148.	0.4	29
668	Amyloidosis: Pathogenesis and New Therapeutic Options. Journal of Clinical Oncology, 2011, 29, 1924-1933.	1.6	430
669	Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplantation, 2011, 46, 970-975.	2.4	63
670	Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood, 2011, 118, 2970-2975.	1.4	193
671	SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. Bone Marrow Transplantation, 2011, 46, 956-961.	2.4	16
672	Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Annals of Hematology, 2011, 90, 101-106.	1.8	39
673	Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2011, 86, 180-186.	4.1	86
674	Changes in serumâ€free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. American Journal of Hematology, 2011, 86, 251-255.	4.1	78
675	WaldenstrÃ¶m macroglobulinemia: 2011 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2011, 86, 411-416.	4.1	22
676	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. American Journal of Hematology, 2011, 86, 640-645.	4.1	57
677	Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrology Dialysis Transplantation, 2011, 26, 2032-2036.	0.7	88
678	Trend toward improved day 100 and two-year survival following stem cell transplantation for AL: a comparison before and after 2006. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 137-138.	3.0	4
679	Deciding on the therapy of multiple myeloma using genetic risk stratification. Leukemia and Lymphoma, 2011, 52, 157-158.	1.3	0
680	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. Blood, 2011, 118, 2887-2887.	1.4	1
681	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. Blood, 2011, 118, 2942-2942.	1.4	2
682	Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies. Blood, 2011, 118, 2950-2950.	1.4	1
683	Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,. Blood, 2011, 118, 3963-3963.	1.4	4
684	Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma,. Blood, 2011, 118, 3981-3981.	1.4	3

#	Article	IF	Citations
685	Bortezomib in Systemic Light-Chain Amyloidosis. , 2011, , 135-148.		0
686	The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation,. Blood, 2011, 118, 4120-4120.	1.4	5
687	Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience. Blood, 2011, 118, 3101-3101.	1.4	0
688	Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy. Blood, 2011, 118, 2992-2992.	1.4	0
689	Matched Case Control Analysis Comparing Long Term Survival of Multiple Myeloma Patients Who Received Stem Cell Transplant with and without Idiotype-Pulsed Dendritic Cell Vaccine. Blood, 2011, 118, 636-636.	1.4	0
690	Treatment of immunoglobulin light chain (primary or AL) amyloidosis. Oncology, 2011, 25, 620-6.	0.5	8
691	Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood, 2010, 115, 2348-2353.	1.4	42
692	I don't know how to treat amyloidosis. Blood, 2010, 116, 507-508.	1.4	27
693	Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood, 2010, 116, 5126-5129.	1.4	146
694	Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients. American Journal of Hematology, 2010, 85, 171-173.	4.1	75
695	A Phase II study of ¹⁵³Smâ€EDTMP and highâ€dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. American Journal of Hematology, 2010, 85, 409-413.	4.1	22
696	Discordance between serum cardiac biomarker and immunoglobulinâ€free lightâ€chain response in patients with immunoglobulin lightâ€chain amyloidosis treated with immune modulatory drugs. American Journal of Hematology, 2010, 85, 757-759.	4.1	111
697	review: Current status of stem cell mobilization. British Journal of Haematology, 2010, 150, 647-662.	2.5	134
698	Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia, 2010, 24, 1934-1939.	7.2	182
699	Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia, 2010, 24, 833-842.	7.2	41
700	Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2010, 28, 1408-1414.	1.6	132
701	Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. Neurology, 2010, 74, 913-918.	1.1	30
702	Plasma cell leukemia. Haematologica, 2010, 95, 705-707.	3.5	15

#	Article	IF	Citations
703	Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplantation, 2010, 45, 1396-1403.	2.4	78
704	Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma. Mayo Clinic Proceedings, 2010, 85, 232-238.	3.0	69
705	Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. Mayo Clinic Proceedings, 2010, 85, 532-537.	3.0	55
706	Amyloidosis and POEMS syndrome. Expert Opinion on Pharmacotherapy, 2010, 11, 1501-1514.	1.8	9
707	Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leukemia and Lymphoma, 2010, 51, 2181-2187.	1.3	102
708	Role of Cardiac Magnetic Resonance Imaging in the Detection of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2010, 3, 155-164.	5.3	431
709	Pitfalls in the Diagnosis of Primary Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 177-180.	0.4	46
710	Managing tumor lysis syndrome in 2010. Leukemia and Lymphoma, 2010, 51, 179-180.	1.3	19
711	High-Dose Chemotherapy with Autotransplantation in AL Amyloidosis: A Flawed Meta-analysis. Biology of Blood and Marrow Transplantation, 2010, 16, 138-140.	2.0	32
712	Diagnosis and Management of WaldenstrÃ¶m Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines. Mayo Clinic Proceedings, 2010, 85, 824-833.	3.0	152
713	Individualizing cancer therapy. Leukemia and Lymphoma, 2010, 51, 1585-1587.	1.3	0
714	Herbs for hematology. Leukemia and Lymphoma, 2010, 51, 1389-1390.	1.3	1
715	What's new in WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2010, 51, 1765-1766.	1.3	1
716	WaldenstrÃ¶m macroglobulinemia: is newer really better?. Leukemia and Lymphoma, 2010, 51, 2152-2153.	1.3	3
717	Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma. Blood, 2010, 116, 1964-1964.	1.4	5
718	Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma.. Blood, 2010, 116, 2802-2802.	1.4	2
719	A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289). Blood, 2010, 116, 3053-3053.	1.4	1
720	Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) Amyloidosis. Blood, 2010, 116, 370-370.	1.4	4

#	Article	IF	Citations
721	A phase II study of pomalidomide and dexamethasone in previously treated light-chain (AL) amyloidosis.. Journal of Clinical Oncology, 2010, 28, 8025-8025.	1.6	2
722	Conventional Treatment of Amyloidosis. , 2010, , 155-164.		0
723	Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide Therapy. Blood, 2010, 116, 1965-1965.	1.4	0
724	Role of Hepcidin In Anemia of Waldenstroì^m Macroglobulinemia. Blood, 2010, 116, 4984-4984.	1.4	0
725	Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches. Blood, 2010, 116, 2253-2253.	1.4	5
726	Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function. Blood, 2010, 116, 2970-2970.	1.4	1
727	Does stem cell transplantation have a role in the management of multiple myeloma, 2009?. Expert Opinion on Pharmacotherapy, 2009, 10, 1-4.	1.8	5
728	Chapter 1 Amyloidosis. Advances in Clinical Chemistry, 2009, , 1-44.	3.7	25
729	Update on Treatment Recommendations From the Fourth International Workshop on WaldenstrÃ¶m's Macroglobulinemia. Journal of Clinical Oncology, 2009, 27, 120-126.	1.6	207
730	Intracardiac Thrombosis and Anticoagulation Therapy in Cardiac Amyloidosis. Circulation, 2009, 119, 2490-2497.	1.6	215
731	Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrology Dialysis Transplantation, 2009, 24, 3132-3137.	0.7	106
732	Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, 5008-5014.	1.6	286
733	Acute weight gain and diastolic dysfunction as a potent risk complex for post stem cell transplant atrial fibrillation. American Journal of Hematology, 2009, 84, 499-503.	4.1	20
734	Treatment of immunoglobulin light chain amyloidosis. Current Hematologic Malignancy Reports, 2009, 4, 91-98.	2.3	27
735	Clinical value of minor responses after 4 doses of rituximab in WaldenstrÃ¶m macroglobulinaemia: a followâ€up of the Eastern Cooperative Oncology Group E3A98 trial. British Journal of Haematology, 2009, 147, 677-680.	2.5	50
736	Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplantation, 2009, 43, 619-625.	2.4	108
737	Multiple Myeloma: Biology, Standard Therapy, and Transplant Therapy. Biology of Blood and Marrow Transplantation, 2009, 15, 46-52.	2.0	6
738	Transplantation for IgM Amyloidosis and IgM Myeloma. Clinical Lymphoma and Myeloma, 2009, 9, 77-79.	1.4	11

#	Article	IF	Citations
739	Caring for the terminally ill patient with hematologic malignancies. Leukemia and Lymphoma, 2009, 50, 313-314.	1.3	1
740	Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia and Lymphoma, 2009, 50, 781-787.	1.3	6
741	Is antisense nonsense?. Leukemia and Lymphoma, 2009, 50, 519-520.	1.3	0
742	Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clinic Proceedings, 2009, 84, 1095-1110.	3.0	389
743	Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1Î²-Induced Interleukin 6 Production and the Myeloma Proliferative Component. Mayo Clinic Proceedings, 2009, 84, 114-122.	3.0	236
744	Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Groupâ€“directed intergroup trial S9003. Blood, 2009, 113, 793-796.	1.4	60
745	The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood, 2009, 114, 2617-2618.	1.4	45
746	Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood, 2009, 114, 518-521.	1.4	130
747	Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica, 2009, 94, 380-386.	3.5	94
748	Depth of Response with Stem Cell Transplantation and Outcome for Multiple Myeloma in the Era of Novel Agents.. Blood, 2009, 114, 1228-1228.	1.4	1
749	Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.. Blood, 2009, 114, 2868-2868.	1.4	3
750	A Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone (RCD) in Patients with Light Chain Amyloidosis.. Blood, 2009, 114, 3853-3853.	1.4	8
751	Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.. Blood, 2009, 114, 956-956.	1.4	1
752	Low risk for symptomatic venous thromboembolic events (vte) during cytokine administration for peripheral blood stem cell mobilization. Journal of Clinical Oncology, 2009, 27, 7039-7039.	1.6	0
753	Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients.. Blood, 2009, 114, 2877-2877.	1.4	0
754	Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma.. Blood, 2009, 114, 3884-3884.	1.4	0
755	Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. American Journal of Hematology, 2008, 83, 614-617.	4.1	123
756	High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis. New England Journal of Medicine, 2008, 358, 91-93.	27.0	36

#	Article	IF	Citations
757	Genetic aberrations and survival in plasma cell leukemia. Leukemia, 2008, 22, 1044-1052.	7.2	299
758	Impact of additional cytoreduction following autologous SCT in multiple myeloma. Bone Marrow Transplantation, 2008, 42, 259-264.	2.4	10
759	Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplantation, 2008, 42, 413-420.	2.4	87
760	Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Bone Marrow Transplantation, 2008, 41, 1013-1019.	2.4	20
761	Reply to â€˜Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patientsâ€™. Leukemia, 2008, 22, 1281-1282.	7.2	32
762	Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. European Journal of Haematology, 2008, 80, 397-406.	2.2	116
763	Current Treatment Options for WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma and Myeloma, 2008, 8, 219-229.	1.4	12
764	Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative. Mayo Clinic Proceedings, 2008, 83, 1131-1135.	3.0	90
765	Autologous Stem Cell Transplant after Heart Transplant for Light Chain (AL) Amyloid Cardiomyopathy. Journal of Heart and Lung Transplantation, 2008, 27, 823-829.	0.6	117
766	Serum Uric Acid: Novel Prognostic Factor in Primary Systemic Amyloidosis. Mayo Clinic Proceedings, 2008, 83, 297-303.	3.0	39
767	The dilemma of jaw osteonecrosis in patients with multiple myeloma. Leukemia and Lymphoma, 2008, 49, 2037-2039.	1.3	2
768	The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma. Leukemia and Lymphoma, 2008, 49, 1436-1451.	1.3	4
769	Current therapy of myeloma induced renal failure. Leukemia and Lymphoma, 2008, 49, 833-834.	1.3	4
770	Troponin in hematologic oncology. Leukemia and Lymphoma, 2008, 49, 194-203.	1.3	10
771	New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression. Leukemia and Lymphoma, 2008, 49, 2240-2245.	1.3	11
772	Improved survival in multiple myeloma and the impact of novel therapies. Blood, 2008, 111, 2516-2520.	1.4	2,022
773	Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leukemia and Lymphoma, 2008, 49, 36-41.	1.3	83
774	Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrology Dialysis Transplantation, 2008, 23, 2052-2057.	0.7	87

#	Article	IF	Citations
775	Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leukemia and Lymphoma, 2008, 49, 1104-1107.	1.3	44
776	Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood, 2008, 111, 785-789.	1.4	355
777	Critiquing Cryos. Blood, 2008, 111, 5267-5267.	1.4	0
778	IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS. , 2008, , 112-128.		0
779	Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis. Haematologica, 2008, 93, 1402-1406.	3.5	22
780	Normalization of the Serum Free Light Chain (FLC) Ratio Is Associated with Superior Overall Survival among Myeloma Patients Achieving Immunofixation Negative State: Results Support Incorporation of Serum FLC Ratio in Stringent CR Definition.. Blood, 2008, 112, 1692-1692.	1.4	6
781	Waldenstrom's Macroglobulinemia. , 2008, , 519-550.		0
782	Amyloidosis: diagnosis and prognosis. Future Rheumatology, 2008, 3, 369-380.	0.2	3
783	The Prevalence of Abnormal Coagulation Parameters in Patients with Newly Diagnosed Primary Systemic Amyloidosis and Its Impact on Outcome. Blood, 2008, 112, 5114-5114.	1.4	0
784	Managing myeloma of the kidney. Leukemia and Lymphoma, 2007, 48, 221-222.	1.3	0
785	Advances in the Treatment of Amyloidosis. New England Journal of Medicine, 2007, 356, 2413-2415.	27.0	58
786	Proteomic Analysis of Waldenstrom Macroglobulinemia. Cancer Research, 2007, 67, 3777-3784.	0.9	56
787	Relationship Between Depth of Response and Outcome in Multiple Myeloma. Journal of Clinical Oncology, 2007, 25, 4933-4937.	1.6	40
788	Severity of Baseline Proteinuria Predicts Renal Response in Immunoglobulin Light Chainâ€“Associated Amyloidosis after Autologous Stem Cell Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 440-444.	4.5	38
789	The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 2007, 109, 465-470.	1.4	259
790	WaldenstrÃ¶m macroglobulinemia. Blood, 2007, 109, 5096-5103.	1.4	183
791	Transplantation for amyloidosis. Current Opinion in Oncology, 2007, 19, 136-141.	2.4	77
792	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. Mayo Clinic Proceedings, 2007, 82, 323-341.	3.0	143

#	Article	IF	Citations
793	Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica, 2007, 92, 1415-1418.	3.5	114
794	Relevant prognostic features of multiple myeloma and the new International Staging System. Leukemia and Lymphoma, 2007, 48, 458-468.	1.3	11
795	Managing plasma cell leukemia. Leukemia and Lymphoma, 2007, 48, 5-6.	1.3	17
796	What is the correct philosophy for the treatment of multiple myeloma?. Leukemia and Lymphoma, 2007, 48, 2298-2299.	1.3	1
797	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. Mayo Clinic Proceedings, 2007, 82, 323-341.	3.0	155
798	Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation, 2007, 39, 605-611.	2.4	57
799	Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). Bone Marrow Transplantation, 2007, 40, 989-993.	2.4	10
800	A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia, 2007, 21, 529-534.	7.2	191
801	Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia, 2007, 21, 2035-2042.	7.2	317
802	6q deletion in WaldenstrÃ¶m macroglobulinemia is associated with features of adverse prognosis. British Journal of Haematology, 2007, 136, 80-86.	2.5	109
803	Management of cold haemolytic syndrome. British Journal of Haematology, 2007, 138, 422-429.	2.5	71
804	InÂvivoandinÂsilicostudies on single versus multiple transplants for multiple myeloma. Cancer Science, 2007, 98, 734-739.	3.9	6
805	Serum M-spike and transplant outcome in patients with multiple myeloma. Cancer Science, 2007, 98, 1035-1040.	3.9	15
806	Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).. Blood, 2007, 110, 241-241.	1.4	1
807	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (clg-FISH).. Blood, 2007, 110, 2477-2477.	1.4	1
808	Perioperative Outcome of Patients with Acquired Factor X Deficiency Associated with AL Amyloidosis: The Mayo Clinic Experience.. Blood, 2007, 110, 3965-3965.	1.4	1
809	Novel Therapeutic Options in Primary Systemic Amyloidosis. Translational Medicine Series, 2007, , 261-276.	0.0	0
810	Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma.. Blood, 2007, 110, 1181-1181.	1.4	0

#	Article	IF	Citations
811	Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis.. Blood, 2007, 110, 3608-3608.	1.4	0
812	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. Blood, 2007, 110, 1492-1492.	1.4	0
813	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. Blood, 2007, 110, 2995-2995.	1.4	0
814	Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient. International Journal of Prosthodontics, 2007, 20, 115-22.	1.7	12
815	When is myeloma, myeloma?. Leukemia and Lymphoma, 2006, 47, 1452-1453.	1.3	0
816	Managing monoclonal gammopathy-associated neuropathy. Leukemia and Lymphoma, 2006, 47, 785-786.	1.3	6
817	Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma. Mayo Clinic Proceedings, 2006, 81, 1047-1053.	3.0	221
818	Autologous Attack on Amyloidosis. Mayo Clinic Proceedings, 2006, 81, 874-876.	3.0	5
819	Update on Recommendations for Assessing Response from the Third International Workshop on WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2006, 6, 380-383.	1.4	107
820	Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 384-388.	1.4	79
821	Response to Rituximab in Patients with Type II Cryoglobulinemia. Clinical Lymphoma and Myeloma, 2006, 7, 140-144.	1.4	33
822	Autologous or Allogeneic Stem Cell Transplantation in Patients with Waldenstromâ€™s Macroglobulinemia. Biology of Blood and Marrow Transplantation, 2006, 12, 845-854.	2.0	68
823	Cold Hemolytic Syndrome. Hematology American Society of Hematology Education Program, 2006, 2006, 19-23.	2.5	54
824	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 2006, 107, 3378-3383.	1.4	230
825	Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood, 2006, 107, 3384-3388.	1.4	64
826	Transplantation for cutaneous disease. Blood, 2006, 107, 415-415.	1.4	0
827	Allo attack on amyloidosis. Blood, 2006, 107, 2213-2214.	1.4	2
828	Gene-expression profiling of Waldenstroì^m macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood, 2006, 108, 2755-2763.	1.4	166

#	Article	IF	Citations
829	Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood, 2006, 108, 1979-1983.	1.4	152
830	Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. British Journal of Haematology, 2006, 133, 158-164.	2.5	128
831	Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia, 2006, 20, 807-813.	7.2	129
832	Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia, 2006, 20, 2034-2040.	7.2	195
833	Ploidy status rarely changes in myeloma patients at disease progression. Leukemia Research, 2006, 30, 266-271.	0.8	31
834	6q deletion discriminates WaldenstrÃ¶m macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genetics and Cytogenetics, 2006, 169, 150-153.	1.0	105
835	Natural history and therapy of 66 patients with mixed cryoglobulinemia. American Journal of Hematology, 2006, 81, 511-518.	4.1	59
836	High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Review of Anticancer Therapy, 2006, 6, 343-360.	2.4	21
837	Autologous stem cell transplantation and IgM amyloidosis. Leukemia and Lymphoma, 2006, 47, 1006-1012.	1.3	19
838	Correlation of bone marrow angiogenesis and response to thalidomide dexamethasone in multiple myeloma. Journal of Clinical Oncology, 2006, 24, 7621-7621.	1.6	1
839	Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents.. Blood, 2006, 108, 3500-3500.	1.4	0
840	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. Blood, 2006, 108, 3587-3587.	1.4	0
841	A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood, 2005, 106, 2156-2161.	1.4	115
842	Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood, 2005, 106, 3353-3357.	1.4	44
843	Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood, 2005, 106, 2837-2840.	1.4	337
844	Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood, 2005, 106, 2276-2279.	1.4	213
845	Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement. Kidney International, 2005, 68, 1464-1471.	5.2	11
846	A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia, 2005, 19, 118-125.	7.2	46

#	Article	IF	Citations
847	Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. American Journal of Cardiology, 2005, 95, 535-537.	1.6	263
848	Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. American Journal of Kidney Diseases, 2005, 45, 102-111.	1.9	34
849	Renal Response After High-Dose Melphalan and Stem Cell Transplantation Is a Favorable Marker in Patients With Primary Systemic Amyloidosis. American Journal of Kidney Diseases, 2005, 46, 270-277.	1.9	74
850	Living Donor Kidney and Autologous Stem Cell Transplantation for Primary Systemic Amyloidosis (AL) with Predominant Renal Involvement. American Journal of Transplantation, 2005, 5, 1660-1670.	4.7	83
851	WaldenstrÃ¶m macroglobulinemia: A review of therapy. American Journal of Hematology, 2005, 79, 147-157.	4.1	22
852	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology, 2005, 79, 319-328.	4.1	1,179
853	Current status of stem cell transplantation for multiple myeloma. Current Treatment Options in Oncology, 2005, 6, 229-240.	3.0	1
854	Managing Myeloma Kidney. Annals of Internal Medicine, 2005, 143, 835.	3.9	17
855	Multicentre versus single centre approach to rare diseases: The model of systemic light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 120-126.	3.0	48
856	Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. European Heart Journal, 2005, 26, 173-179.	2.2	90
857	Early Results of a Phase I Trial of Oblimersen Sodium for Relapsed or Refractory WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2005, 5, 282-284.	2.1	24
858	Cold Agglutinin Disease and Cryoglobulinemia. Clinical Lymphoma and Myeloma, 2005, 5, 290-293.	2.1	32
859	Amyloidosis: Diagnosis and Management. Clinical Lymphoma and Myeloma, 2005, 6, 208-219.	1.4	54
860	Amyloidosis. Best Practice and Research in Clinical Haematology, 2005, 18, 709-727.	1.7	68
861	The Role of Stem Cell Mobilization Regimen on Lymphocyte Collection Yield and Survival after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.. Blood, 2005, 106, 1174-1174.	1.4	2
862	Incidence and Clinical Course of Peripheral Neuropathy in Patients Receiving Thalidomide for the Treatment of Multiple Myeloma.. Blood, 2005, 106, 3475-3475.	1.4	6
863	Immunoglobulin Free Light Chains at Diagnosis: Predictors of Progression and Survival in Solitary Plasmacytoma of Bone.. Blood, 2005, 106, 5080-5080.	1.4	1
864	Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.. Blood, 2005, 106, 781-781.	1.4	5

#	Article	IF	Citations
865	Flow Cytometric Detection of Circulating Myeloma Cells Pretransplant in Patients with Multiple Myeloma: A Simple Risk Stratification System.. Blood, 2005, 106, 1164-1164.	1.4	7
866	6q Deletion in Waldenstroì^m Macroglobulinemia Is the Most Common Cytogenetic Abnormality and Is Associated with Aggressive Disease with a Trend towards Worse Survival.. Blood, 2005, 106, 986-986.	1.4	2
867	Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 5420-5420.	1.4	0
868	Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.. Blood, 2005, 106, 3381-3381.	1.4	0
869	Autologous Stem Cell Transplantation for Multiple Myeloma in Patients over 70 Years: A Matched Comparison with Patients under 65 Years.. Blood, 2005, 106, 1173-1173.	1.4	1
870	Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Transplanted for Multiple Myeloma.. Blood, 2005, 106, 1165-1165.	1.4	0
871	In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated with Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrate a Significantly Increased Time to Progression (TTP) and a Decreased C-Reactive Protein (CRP) Compared with Nonresponders.. Blood, 2005, 106, 2567-2567.	1.4	2
872	The t(4;14) Is Present in Patients with Early Stage Plasma Cell Proliferative Disorders Including MGUS and Smoldering Multiple Myeloma (SMM).. Blood, 2005, 106, 1545-1545.	1.4	2
873	Comparison of Myeloma Cell Gene Expression Profiles Pre and Post Thalidomide - Dexamethasone Therapy Provides Insight into Potential Mechanisms.. Blood, 2005, 106, 3480-3480.	1.4	0
874	Allogeneic Stem Cell Transplantation (ASCT) and Donor Lymphocyte Infusions (DLI) in the Management of Chronic Myelomonocytic Leukemia (CMML).. Blood, 2005, 106, 5422-5422.	1.4	0
875	One Half of Patients with Waldenstroì^m Macroglobulinemia Have Large Deletions of Chromosome 6q.. Blood, 2005, 106, 1546-1546.	1.4	0
876	Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clinical Cancer Research, 2005, 11, 1210-8.	7.0	42
877	Multicenter Phase 2 Trial of Rituximab for WaldenstrÃ¶m Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leukemia and Lymphoma, 2004, 45, 2047-2055.	1.3	193
878	Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis. Journal of Clinical Oncology, 2004, 22, 3751-3757.	1.6	774
879	The Classification and Typing of Amyloid Deposits. American Journal of Clinical Pathology, 2004, 121, 787-789.	0.7	48
880	Amyloidosis and Waldenstroì^mâ€™s Macroglobulinemia. Hematology American Society of Hematology Education Program, 2004, 2004, 257-282.	2.5	78
881	A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplantation, 2004, 34, 149-154.	2.4	40
882	High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplantation, 2004, 34, 161-167.	2.4	82

#	Article	IF	Citations
883	Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplantation, 2004, 34, 485-490.	2.4	52
884	Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplantation, 2004, 34, 1025-1031.	2.4	102
885	Long-term outcome of renal transplantation in light-chain deposition disease. American Journal of Kidney Diseases, 2004, 43, 147-153.	1.9	187
886	Analysis of Somatic Hypermutation and Antigenic Selection in the Clonal B Cell in Immunoglobulin Light Chain Amyloidosis (AL). Journal of Clinical Immunology, 2004, 24, 340-353.	3.8	24
887	Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Reviews, 2004, 18, 17-37.	5.7	59
888	Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to WaldenstrÃ¶m macroglobulinemia does not indicate failure of response. American Journal of Hematology, 2004, 77, 329-330.	4.1	44
889	Initial immunoglobulin M ?flare? after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia. Cancer, 2004, 101, 2593-2598.	4.1	190
890	Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood, 2004, 104, 3400-3407.	1.4	204
891	Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 2004, 104, 1881-1887.	1.4	300
892	Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood, 2004, 104, 40-42.	1.4	128
893	Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood, 2004, 103, 3960-3963.	1.4	226
894	Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkinâ€™s Lymphoma.. Blood, 2004, 104, 2927-2927.	1.4	1
895	Combination Therapy with CC-5013 (Lenalidomide; Revlimidâ„¢) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).. Blood, 2004, 104, 331-331.	1.4	16
896	Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.. Blood, 2004, 104, 892-892.	1.4	2
897	The Classification and Typing of Amyloid Deposits. American Journal of Clinical Pathology, 2004, 121, 787-789.	0.7	19
898	Characterization of Waldenstroˆm Macroglobulinemia Subtypes using Global Gene Expression Profiling.. Blood, 2004, 104, 786-786.	1.4	0
899	Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) Identifies Potential Targets for Drug Therapy.. Blood, 2004, 104, 787-787.	1.4	0
900	Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience.. Blood, 2004, 104, 928-928.	1.4	0

#	Article	IF	Citations
901	The Mayo Clinic Experience with 66 Patients with Type II Cryoglobulinemia.. Blood, 2004, 104, 1493-1493.	1.4	0
902	Oncolytic Measles Virus Selectively Targets CD46 Overexpression on Myeloma Cells.. Blood, 2004, 104, 2392-2392.	1.4	0
903	Interleukin-1 Receptor Antagonist (IL-1Ra) Targets the Proliferative Component in Early Stage Myeloma.. Blood, 2004, 104, 2412-2412.	1.4	1
904	Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 121-126.	2.2	94
905	Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SWOG S9003). Seminars in Oncology, 2003, 30, 220-225.	2.2	61
906	Amyloidosis with IgM monoclonal gammopathies. Seminars in Oncology, 2003, 30, 325-328.	2.2	51
907	Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplantation, 2003, 32, 587-592.	2.4	30
908	Autologous stem cell transplantation in multiple myeloma patients <60 vs â©¾60 years of age. Bone Marrow Transplantation, 2003, 32, 1135-1143.	2.4	70
909	Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia, 2003, 17, 427-436.	7.2	208
910	Thalidomide as initial therapy for early-stage myeloma. Leukemia, 2003, 17, 775-779.	7.2	219
911	Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet, The, 2003, 361, 1787-1789.	13.7	277
912	WaldenstrÃ¶m macroglobulinaemia. Lancet Oncology, The, 2003, 4, 679-685.	10.7	138
913	Review of 1027 Patients With Newly Diagnosed Multiple Myeloma. Mayo Clinic Proceedings, 2003, 78, 21-33.	3.0	1,904
914	POEMS syndrome: definitions and long-term outcome. Blood, 2003, 101, 2496-2506.	1.4	694
915	Quantitative Analysis of Serum Free Light Chains. American Journal of Clinical Pathology, 2003, 119, 274-278.	0.7	176
916	Localized AL amyloidosis of the colon: an unrecognized entity. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 36-41.	3.0	25
917	Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 257-261.	3.0	126
918	Primary (AL) Hepatic Amyloidosis. Medicine (United States), 2003, 82, 291-298.	1.0	201

#	Article	IF	Citations
919	Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood, 2003, 101, 827-830.	1.4	69
920	Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chainâ€“associated amyloidosis (AL). Blood, 2003, 101, 3801-3807.	1.4	207
921	The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood, 2003, 102, 2562-2567.	1.4	257
922	Caring (Really) for Patients Who Use Alternative Therapies for Cancer. Journal of Clinical Oncology, 2003, 21, 125s-128.	1.6	8
923	Immunoglobulin light chain amyloidosis and the kidney. , 2003, , 215-226.		0
924	Transplantation for multiple myeloma. Pertinent Questions. Blood, 2003, 102, 3472-5.	1.4	4
925	Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma. Journal of Clinical Oncology, 2002, 20, 4319-4323.	1.6	479
926	WaldenstrÃ¶m's Macroglobulinemia: A Review of Therapy. Leukemia and Lymphoma, 2002, 43, 1517-1526.	1.3	9
927	A multicenter phase II trial of 4â€²-iodo-4â€²-deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 24-30.	3.0	54
928	Autologous stem cell transplantation for primary systemic amyloidosis. Blood, 2002, 99, 4276-4282.	1.4	335
929	Stem cell transplantation for the management of primary systemic amyloidosis. American Journal of Medicine, 2002, 113, 549-555.	1.5	157
930	Current Therapy for Multiple Myeloma. Mayo Clinic Proceedings, 2002, 77, 813-822.	3.0	97
931	Primary Localized Amyloidosis of The bladder:: Experience With Dimethyl Sulfoxide Therapy. Journal of Urology, 2002, 168, 1018-1020.	0.4	43
932	Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood, 2002, 100, 1417-1424.	1.4	317
933	Deletions of 17p13.1 and 13q14 are uncommon in WaldenstrÃ¶m macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genetics and Cytogenetics, 2002, 132, 55-60.	1.0	55
934	Primary systemic amyloidosis. Current Treatment Options in Oncology, 2002, 3, 261-271.	3.0	48
935	Immunoglobulin light chain amyloidosis and the kidney. Kidney International, 2002, 61, 1-9.	5.2	94
936	Cutaneous and systemic amyloidoses. International Journal of Dermatology, 2002, 41, 133-134.	1.0	10

#	Article	IF	Citations
937	Myeloma and the newly diagnosed patient: A focus on treatment and management. Seminars in Oncology, 2002, 29, 5-10.	2.2	87
938	Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood, 2002, 100, 1417-24.	1.4	117
939	Primary systemic amyloidosis: a cause of malabsorption syndrome. American Journal of Medicine, 2001, 111, 535-540.	1.5	65
940	Eligibility for Hematopoietic Stem-Cell Transplantation for Primary Systemic Amyloidosis Is a Favorable Prognostic Factor for Survival. Journal of Clinical Oncology, 2001, 19, 3350-3356.	1.6	154
941	Caring (Really) for Patients Who Use Alternative Therapies for Cancer. Journal of Clinical Oncology, 2001, 19, 4346-4349.	1.6	15
942	A high bone marrow plasma cell labeling index in stable plateauâ€“phase multiple myeloma is a marker for early disease progression and death. Blood, 2001, 97, 2522-2523.	1.4	50
943	Prognostic factors and response to fludarabine therapy in patients with Waldenstrol̂m macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood, 2001, 98, 41-48.	1.4	153
944	Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood, 2001, 98, 579-585.	1.4	253
945	Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood, 2001, 98, 2266-2268.	1.4	135
946	Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation. American Journal of Hematology, 2001, 68, 269-275.	4.1	61
947	High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. Bone Marrow Transplantation, 2001, 28, 381-385.	2.4	42
948	Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2001, 27, 1299-1303.	2.4	119
949	WaldenstrÃ¶m's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. British Journal of Haematology, 2000, 108, 737-742.	2.5	139
950	Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplantation, 2000, 26, 979-983.	2.4	55
951	Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplantation, 2000, 26, 963-969.	2.4	88
952	Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplantation, 2000, 25, 465-470.	2.4	72
953	Five or more years of survival in patients with primary systemic amyloidosis and biopsy-proven cardiac involvement. American Journal of Cardiology, 2000, 85, 664-665.	1.6	25
954	Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplantation, 2000, 26, 45-50.	2.4	33

#	Article	IF	Citations
955	FISH Demonstrates Treatment-Related Chromosome Damage in Myeloid but not Plasma Cells in Primary Systemic Amyloidosis. Leukemia and Lymphoma, 2000, 39, 391-395.	1.3	11
956	Fatal Pulmonary Toxicity Related to the Administration of Granulocyte Colony-Stimulating Factor in Amyloidosis: A Report and Review of Growth Factor-Induced Pulmonary Toxicity. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 635-643.	1.8	35
957	WaldenstrÃ¶m's Macroglobulinemia. Oncologist, 2000, 5, 63-67.	3.7	104
958	Prospective Randomized Trial of Melphalan and Prednisone Versus Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Primary Systemic Amyloidosis. Journal of Clinical Oncology, 1999, 17, 262-262.	1.6	77
959	Plasmablastic Morphology Is an Independent Predictor of Poor Survival After Autologous Stem-Cell Transplantation for Multiple Myeloma. Journal of Clinical Oncology, 1999, 17, 1551-1551.	1.6	64
960	Long-Term Survival (10 Years or More) in 30 Patients With Primary Amyloidosis. Blood, 1999, 93, 1062-1066.	1.4	180
961	Clinical Significance of the Translocation (11;14)(q13;q32) in Multiple Myeloma. Leukemia and Lymphoma, 1999, 35, 599-605.	1.3	31
962	VIII International Symposium on Amyloidosis, August 7-11,1998, Rochester, MN. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1999, 6, 59-62.	3.0	0
963	Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplantation, 1999, 23, 221-226.	2.4	34
964	Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplantation, 1999, 23, 1261-1266.	2.4	31
965	Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplantation, 1999, 23, 1267-1272.	2.4	61
966	Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Medical Oncology and Tumor Pharmacotherapy, 1999, 16, 104-109.	1.1	47
967	Cytogenetic Abnormalities Correlate with the Plasma Cell Labeling Index and Extent of Bone Marrow Involvement in Myeloma. Cancer Genetics and Cytogenetics, 1999, 113, 73-77.	1.0	91
968	Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. , 1999, 61, 115-119.		40
969	AMYLOIDOSIS. Hematology/Oncology Clinics of North America, 1999, 13, 1211-1233.	2.2	141
970	Amyloidosis: Recognition, Confirmation, Prognosis, and Therapy. Mayo Clinic Proceedings, 1999, 74, 490-494.	3.0	49
971	Amyloidosis: Recognition, Confirmation, Prognosis, and Therapy. Mayo Clinic Proceedings, 1999, 74, 490-494.	3.0	108
972	Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood, 1999, 93, 1062-6.	1.4	57

#	Article	IF	Citations
973	Primary systemic amyloidosis with delayed progression to multiple myeloma. , 1998, 82, 1501-1505.		105
974	Detection of monoclonal plasma cells in the peripheral blood of patients with primary amyloidosis. British Journal of Haematology, 1998, 100, 326-327.	2.5	14
975	Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. British Journal of Haematology, 1998, 101, 296-301.	2.5	70
976	CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGHâ€DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION. British Journal of Haematology, 1998, 102, 1115-1123.	2.5	1,380
977	Chromosomal abnormalities in systemic amyloidosis. British Journal of Haematology, 1998, 103, 704-710.	2.5	49
978	Prognosis of Patients with Primary Systemic Amyloidosis Who Present with Dominant Neuropathy 11Supported in part by the Quade Amyloidosis Research Foundation and Program Project Grant No. CA 62242, National Cancer Institute (National Institutes of Health).. American Journal of Medicine, 1998, 104, 232-237.	1.5	135
979	Fibrinogen Aa Chain Leu 554: an African-American kindred with late onset renal amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 188-192.	3.0	16
980	Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer, 1998, 82, 1501-1505.	4.1	3
981	Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer, 1998, 82, 1501-5.	4.1	27
982	A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine. New England Journal of Medicine, 1997, 336, 1202-1207.	27.0	656
983	Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplantation, 1997, 19, 337-342.	2.4	81
984	Factors influencing platelet recovery after blood cell transplantation in multiple myeloma. Bone Marrow Transplantation, 1997, 20, 375-380.	2.4	18
985	Hepatic amyloidosis: Clinical appraisal in 77 patients. Hepatology, 1997, 25, 118-121.	7.3	106
986	Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). , 1997, 56, 288-293.		54
987	Endomyocardial biopsy-proven light chain amyloidosis (AL) without echocardiographic features of infiltrative cardiomyopathy. American Journal of Cardiology, 1997, 80, 93-5.	1.6	6
988	The premortem recognition of systemic senile amyloidosis with cardiac involvement. American Journal of Medicine, 1996, 101, 395-400.	1.5	159
989	Pulmonary Amyloidosis. The Mayo Clinic Experience from 1980 to 1993. Annals of Internal Medicine, 1996, 124, 407.	3.9	315
990	Myopathy in primary systemic amyloidosis.. Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 655-660.	1.9	76

#	Article	IF	Citations
991	Effects of whole blood flow rates on mononuclear cell yields during peripheral blood stem cell collection using fenwal CS 3000 plus. Journal of Clinical Apheresis, 1995, 10, 7-11.	1.3	25
992	Exocrine pancreatic insufficiency after allogeneic bone marrow transplantation. International Journal of Gastrointestinal Cancer, 1995, 17, 243-247.	0.4	11
993	Hyperviscosity Syndrome. Journal of Intensive Care Medicine, 1995, 10, 128-141.	2.8	135
994	Serial Studies of Peripheral Blood Myeloma Cells in Patients with Multiple Myeloma: When is the Optimal Time for Stem Cell Harvest?. Leukemia and Lymphoma, 1995, 19, 417-422.	1.3	8
995	Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Seminars in Hematology, 1995, 32, 45-59.	3.4	882
996	A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia, 1995, 9, 2115-8.	7.2	39
997	Transthyretin VAL107, a new variant associated with familial cardiac and neuropathic amyloidosis. Human Mutation, 1994, 3, 399-401.	2.5	15
998	Amyloidosis: Prognosis and treatment. Seminars in Arthritis and Rheumatism, 1994, 24, 124-138.	3.4	102
999	Phase II trial of recombinant interferon alfa-2 in the treatment of primary systemic amyloidosis. American Journal of Hematology, 1993, 44, 125-128.	4.1	34
1000	Second malignancies after chemotherapy and transplantation. Critical Reviews in Oncology/Hematology, 1993, 14, 107-125.	4.4	5
1001	Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and WaldenstrÃ¶m's macroglobulinemia.. Journal of Clinical Oncology, 1993, 11, 914-920.	1.6	164
1002	Dialysis Support of Patients With Primary Systemic Amyloidosis. Archives of Internal Medicine, 1992, 152, 2245.	3.8	83
1003	Amyloid Localized to Tenosynovium at Carpal Tunnel Release: Immunohistochemical Identification of Amyloid Type. American Journal of Clinical Pathology, 1992, 97, 250-253.	0.7	68
1004	Familial Amyloidosis: A Study of 52 North American-Born Patients Examined During a 30-Year Period. Mayo Clinic Proceedings, 1992, 67, 428-440.	3.0	103
1005	Secondary amyloidosis (AA). Journal of Internal Medicine, 1992, 232, 517-518.	6.0	39
1006	Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients. Archives of Internal Medicine, 1992, 152, 2245-2250.	3.8	18
1007	Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood, 1992, 79, 1817-22.	1.4	174
1008	Cranial neuropathy associated with primary amyloidosis. Annals of Neurology, 1991, 29, 451-454.	5.3	52

#	Article	IF	Citations
1009	Computed tomography for diagnosis of hepatic rupture in primary systemic amyloidosis. American Journal of Hematology, 1991, 37, 194-196.	4.1	38
1010	Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study.. Circulation, 1991, 83, 808-816.	1.6	347
1011	Secondary Systemic Amyloidosis. Medicine (United States), 1991, 70, 246-256.	1.0	253
1012	Classification of amyloidosis by the detection of clonal excess of plasma cells in the bone marrow. Translational Research, 1991, 118, 33-9.	2.3	25
1013	Response rates and survival in primary systemic amyloidosis. Blood, 1991, 77, 257-62.	1.4	32
1014	Phase II trial of Î±-tocopherol (vitamin E) in the treatment of primary systemic amyloidosis. American Journal of Hematology, 1990, 34, 55-58.	4.1	19
1015	Acute Leukemia and Cytogenetic Abnormalities Complicating Melphalan Treatment of Primary Systemic Amyloidosis. Archives of Internal Medicine, 1990, 150, 629.	3.8	41
1016	Beta2-microglobulin predicts survival in primary systemic amyloidosis. American Journal of Medicine, 1990, 89, 609-614.	1.5	27
1017	Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Archives of Internal Medicine, 1990, 150, 629-633.	3.8	18
1018	Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Archives of Internal Medicine, 1990, 150, 629-33.	3.8	6
1019	Primary Systemic Amyloidosisâ€"a Diagnostic Primer. Mayo Clinic Proceedings, 1989, 64, 1505-1519.	3.0	235
1020	Recognition of congestive heart failure due to senile cardiac amyloidosis. Biomedicine and Pharmacotherapy, 1989, 43, 101-106.	5.6	14
1021	The plasma cell labeling index: a valuable tool in primary systemic amyloidosis. Blood, 1989, 74, 1108-11.	1.4	9
1022	Hepatic amyloidosis (Primary [AL], immunoglobulin light chain): The natural history in 80 patients. American Journal of Medicine, 1988, 85, 73-80.	1.5	136
1023	Utility of Subcutaneous Fat Aspiration for the Diagnosis of Systemic Amyloidosis (Immunoglobulin) Tj ETQq1 1 0.784314 rgBT /Overlo	3.8	95
1024	Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobulin) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.8	19
1025	Synovial fluid analysis for diagnosis of amyloid arthropathy. Arthritis and Rheumatism, 1987, 30, 419-423.	6.7	29
1026	Primary amyloidosis (AL) in families. American Journal of Hematology, 1986, 22, 193-198.	4.1	14

#	Article	IF	Citations
1027	Jaw Claudication in Primary Systemic Amyloidosis. Medicine (United States), 1986, 65, 173-179.	1.0	73
1028	Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. American Journal of Cardiology, 1985, 55, 1645.	1.6	136
1029	Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. American Journal of Medicine, 1985, 79, 708-716.	1.5	159
1030	Hematopoietic cell transplantation for immunoglobulin light chain (AL) amyloidosis. , 0, , 477-484.		0
1031	Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL-) Amyloidosis. , 0, , 914-930.		0
1032	Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome. Frontiers in Endocrinology, 0, 13, .	3.5	0